# REVIEW — KB Self-Audit Log

Every ~6th run (§7 REFLECT), the routine steps back from finding names to audit the KB's own health, then makes corrective edits the same run. This is the append-only log of those audits: what was checked, what was wrong, what changed, and the systemic fix to carry forward.

Three standing questions:
1. **Right input data?** Are financials quote-anchored, checker-passed, filing-verified — or thin/unverified? (A CANDIDATE graded without a solid baseline is a defect.)
2. **Exploring the universe well?** Sector coverage (5-19 vs. re-mining 0-4), geographic spread, hit-rate trend, grade mix.
3. **False negatives?** Re-check a couple of recent triage-kills with real numbers — did we wrongly kill a good name on a snippet?

---

## Audit log

### 2026-07-18 — Candidate-list prune (multi-agent workflow) surfaced the biggest systemic leak
- **What:** 33 deep-dived names assessed for genuine asymmetry → only **10 kept** (FAA.VI, EUZ.DE, GENC, PDEX, ELVA, ANIK, FEW.F, CEMX.TO, 6743.T, LBL.AX); 23 culled.
- **The pattern (root cause):** almost every reject was a *genuinely good business* where the **asymmetry wasn't available at today's price** — already re-rated / near 52-wk high (4549.T, HURC, ETON, IOF.L, EPEN.ST), at consensus fair value (CGS.L, CODA, EKF.L, SINT.ST, REC.L), upside capped <2x or symmetric/inverted (DETEC.HE, OFLX, KVHI, SMID, HBB, KMK), slow multi-year grind with no dated trigger (HURC, OFLX, JOUT, 6742.T), or structural-discount value traps (CIX, NATR). The routine was qualifying on **moat + quality** but not on whether the **mispricing was still on the table.**
- **Fix shipped:** added the **Asymmetry Gate** (METHOD.md + ROUTINE §4) — a name qualifies as CANDIDATE+ only if entry is still open (not near high / not at PT / not already 2x'd), realistic bull ≥~2x, payoff skewed, and a *discrete* trigger or CORE-grade quality. Fail → PARK, not CANDIDATE. Diffuse catalysts (cycle-turns / buyback-someday / analyst-may-notice / coverage-void-alone) explicitly don't count.
- **Next systemic fix:** the gate needs the §3.5 baseline to carry 52-wk range + analyst PT so it can be applied mechanically; ensure fetchers pull those two fields.


### 2026-07-18 — Baseline established (methodology upgrade, not an automated run)
- **Data quality:** Financial diligence just moved from snippet-based to a mandatory §3.5 baseline: quote-anchored fetch (haiku) + deterministic `tools/fin_check.py` reconciliation + calibrated trust tags + filing verification in deep-dive. Earlier memos (runs 1–39) were graded WITHOUT this — treat their financial figures as provisional until re-verified. **Action for next REFLECT runs:** re-verify the financial baselines of the current WATCH/CORE/CATALYST names (GENC, EUZ.DE, ELVA.TO) and top CANDIDATEs (ANIK, CODA) against primary filings; downgrade any that don't hold to NEEDS-DATA.
- **Universe:** Sectors 0–4 exhausted; expanded to 20 sectors + geo lens (fixed this session). Early new-sector runs (5–19) are landing (Winmark, HNL.DE, etc.). Watch that runs actually advance the cursor into 5-19 rather than drifting back.
- **False negatives:** Not yet audited. The ~600+ triage-kills from runs 1–39 were snippet-based; a sample should be re-checked once §3.5 is live.
- **Systemic fix to carry forward:** the two-tier "fetch cheap / reason well" split + deterministic checker is the durable lever; keep pushing quality into *structure* (scripts, quote-anchors), not *exhortation*.

### 2026-07-18 — §7 REFLECT run #42 (42%3=0)
- **Bench re-pricing:** snapshot.py blocked (Yahoo Finance not accessible in remote execution environment) → fell back to web searches for all 13 bench names. Prices as of 2026-07-18: WINA $385.44, CODA $9.84-$10.00, OFLX ~$29.85 (~$308M cap), JOUT $46.25, SMID $30.22, ETON $37.57, DETEC.HE ~€11.25 (ambiguous — €8.38 cited June 26; €11.25 stated as "last close"; likely more recent; flagged as SINGLE-SOURCE), EKF.L 25.4p, 6823.T ¥3,485, 6742.T ¥608, CGS.L ~338p (June 29), EPEN.ST 156.20 SEK, 4549.T ~¥3,050+ (near 52-wk high per earlier data; not fresh-searched).
- **Buy-zone triggered: 6742.T Kyosan Electric ¥608 < ¥720 buy-zone.** However: ⚑non-EN (Japan TSE, J-GAAP only); already in UNIVERSE.md as CANDIDATE Grade C (C=3); requires primary-language yuho verification before promotion to QUEUED_HOT. Flagged but NOT auto-promoted.
- **CODA approaching buy-zone:** at $9.84-$10.00, at the upper boundary of $8-10 buy-zone. Not yet triggered. Monitor.
- **Right input data:** All 13 bench prices are web-search-sourced (trust ~), not snapshot.py verified. Non-EN filers (6742.T, 6823.T, 4549.T) have additional trust caps. The buy-zone trigger for 6742.T must be verified from snapshot.py or live quote before acting.
- **Universe exploration:** Run #42 sector 14 Japan geo lens; 5889.T CANDIDATE Grade B/C is the only new name promoted. 4668.T Meiko PARK 5/12 confirmed (no moat + structural juku decline). Running total 63 names.
- **False negatives:** Not formally audited this run. The ~600+ prior triage-kills remain unaudited; systematic re-check deferred to a future REFLECT run once snapshot.py access is restored.
- **Systemic fix to carry forward:** The web-search fallback for bench re-pricing works but is trust-capped. Priority: restore snapshot.py or implement an alternative reliable price feed so bench updates are ✓-trust rather than ~-trust.

### 2026-07-18 — Ironclad price/valuation via public API (not LLM web-reading)
- **Problem:** even with quote-anchoring, an LLM reading price/market-cap/revenue off web pages isn't trustworthy; and the 52-week framing was noise.
- **Fix:** `tools/snapshot.py TICKER` — live price (Yahoo chart, no auth, US+foreign) + most-recent revenue/GM/net-income/shares from **SEC EDGAR XBRL** (primary filing), then **computes market cap = live price × shares** and P/S, P/E itself (no aggregator trust). Handles the dual-class / stale-cover-page trap (falls back to weighted-avg diluted; flags staleness so a wrong market cap can't ship). Foreign filers → live price only, cap C≤2.
- **Caught a real error:** GENC cover-page tag was stale (2014, 8.0M shares) → would have printed a $128M market cap; true current count is 14.66M → **$235M** cap, P/S 1.92, P/E 13.7. Exactly the silent false-precision we were worried about.
- **Gate change:** dropped the 52-week-range test entirely. Entry test is now purely **live price vs. fair value** — the gap is the asymmetry.
- **Next:** extend snapshot.py to also pull cash/total_debt from SEC XBRL (CashAndCashEquivalents, Debt tags) so net-cash is API-sourced too, not fetcher-read.

### 2026-07-18 — Memo red-team (FAA/ELVA/PDEX external critique) → Opus adversarial pass added
- **What happened:** a separate deep human+Claude review of three shortlist memos found the SAME class of errors in all three: **fabricated/stale load-bearing numbers presented as verified** (FAA wrong auditor + invented founding family + backwards concentration; PDEX "20% GM" was 31%; ELVA stale $9.59 price anchor), **one-offs inflating a "cheap" multiple** (PDEX Monogram gain → really ~24x not 17x), **absence-of-catalyst scored as catalyst** (FAA R=5 on "coverage void"), **survivorship base rates** (FAA "3 of 4 re-rated" = the winners), **hard-rule overrides** (FAA granted A with C=3), **revenue-quality mislabeling** (FAA "recurring" = services; PDEX growth cannibalizing high-margin repair), **missed thesis-flipping disclosures** (PDEX 2028 contract extension), **unfalsifiable triggers** (PDEX Sept-3 EPS is CVR-contaminated), and **asymmetry already captured** (ELVA spiked 40%, gap paid out).
- **Fix shipped:** METHOD.md **Adversarial Red-Team (12 failure modes)** + a mandatory **OPUS pass on every cleared candidate** (§5) whose job is to BREAK the thesis and output a **RISK PROFILE** (load-bearing assumption, clean operating earnings & what it's actually worth, informative trigger, moat durability 3/5/10yr, revenue-quality decomposition, the disclosure that would flip it, return if nothing re-rates). A name is CONFIRMED only after surviving all 12.
- **Applied to the motivating names:** FAA.VI, PDEX, ELVA all flagged RED-TEAM FAILED in DIGEST with corrected reads (FAA → Bench high-single-digit compounder; PDEX → HOLD ~24x clean; ELVA → asymmetry spent).
- **Deepest lesson (the cascade):** one fabricated number becomes a confident false narrative downstream — the critic himself built a whole "no pricing power" thesis on PDEX's fake 20% GM. The only defense is **re-derive every load-bearing number from the primary filing for a single stated period BEFORE reasoning**, and treat "too good to be true" as a data alarm.

### 2026-07-20 — §7 REFLECT run #45 (45%3=0)

**1. Data quality audit (last 2 memos):**
- **RSL2.DE-2026-07-20.md** (R. Stahl AG): Correctly PARKed Grade D (Q3/F2/R1/C3). ATEX/IECEx process moat real, but revenue declining 3 years, EBIT near-zero FY2026, FCF burning, net debt growing, analyst PT only +12% above price. Memo correctly flags "Financials verified against primary filing: NO" (web-search-sourced, not primary-filing anchored). Triage kill reason update: TSTL.L COVERAGE_KILL applied correctly.
- **HNL.DE-2026-07-19.md** (Dr. Hönle AG): Correctly PARKed Grade D (Q2/F2/R2/C3). UV curing process moat real but 3 German analysts (not 0 as scouted), stale price anchor, and EV/Revenue 0.94x with €38.8M debt (not "0.55x P/S cheap" as triage snippet claimed). Memo correctly identifies these data errors and flags no primary filing verification.
- **Both memos properly formatted.** The "Financials verified against primary filing: NO" flag is the correct call in both cases — these are web-search-sourced baselines, not primary-filing anchored. No data quality defects found in these two memos beyond already-noted limitations.

**2. Kill list description errors — corrected this run:**
- **TPE.DE entry**: Kill list incorrectly described TPE.DE as "Technotrans SE (Xetra: TTR1.DE)" — a completely different company. TPE.DE is **PVA TePla AG** (SiC crystal growth furnaces + plasma systems + acoustic microscopy for semiconductor wafer inspection; ~70% semiconductor segment). Technotrans SE is TTR1.DE (thermal management for printing). The CAP_KILL conclusion was still correct (PVA TePla confirmed at ~€822M cap + 8 analysts = CAP_KILL + COVERAGE_KILL), but the company description was wrong. Fixed in KILL-LIST this run.
- **ELG.DE entry**: Kill list described ELG.DE as "ElringKlinger AG" — incorrect. ElringKlinger is ELK.DE. ELG.DE is **Elmos Semiconductor SE** (automotive ICs for LiDAR, driver assistance, ultrasonic park assist; ~€600-900M cap). CAP_SOFT_KILL conclusion remains correct. Fixed in KILL-LIST this run.
- **Root cause:** Company-ticker confusion when processing German XTRA names under time pressure. The analytical kill decision was correct in both cases; only the description field was wrong. **Systemic fix:** verify company name matches ticker via primary source (company website or official exchange listing) before writing kill list entry.

**3. False negatives re-checked:**
- **KRMD (KORU Medical Systems):** Correctly PARKed in UNIVERSE.md (quality=0, growth-stage losses, regulatory moat real but no earnings floor). The prior mention of "CAP_KILL (~$400M+, 9 analysts)" was a mis-citation — KRMD is not in KILL-LIST, it's in UNIVERSE as PARK 4/12. Current cap ~$179M, 5 analysts confirmed — PARK status correct (quality=0 blocks promotion regardless of cap or coverage). No change needed.
- **6742.T (Kyosan Electric):** Prior REFLECT (run #42) flagged ¥608 < ¥720 buy-zone as "BUY-ZONE TRIGGERED." Confirmed WRONG — current price ¥864 (confirmed by Agent 1 web search 2026-07-18), which is ABOVE the ¥720 buy-zone. The ¥608 figure was a stale/wrong source. WATCHLIST.md corrected this run: 6742.T flag removed, price updated to ¥864 (above buy-zone). No buy-zone trigger.

**4. Bench re-pricing (2026-07-20):**
All bench prices confirmed by web search agents (trust ~ not ✓ — snapshot.py remains blocked). Key finding:

| Ticker | Last price | Buy-zone | Status |
|---|---|---|---|
| WINA | ~$385.44 | ≤ ~20–22x PE | Above buy-zone |
| CODA | ~$9.84–$10.00 | $8–10 | Approaching (at upper boundary) |
| OFLX | ~$29.85 (~$308M) | ~$190–220M cap | Above buy-zone |
| DETEC.HE | **€8.38–8.70** | **≤€9.5** | **⚠ IN BUY-ZONE** |
| 4549.T | ~¥3,050+ | ¥2,000–2,400 | Above buy-zone |
| 6823.T (Rion) | ~¥3,485 | ¥2,200–2,400 | Above buy-zone |
| EKF.L | ~25.4p | ≤£80M cap (~14–16p) | Above buy-zone |
| 6742.T (Kyosan) | **¥864** | ¥720 | Above buy-zone (prior ¥608 flag was WRONG) |
| CGS.L | ~338p | 200–230p | Above buy-zone |
| EPEN.ST | ~156.20 SEK | 115–130 SEK | Above buy-zone |
| JOUT | ~$46.25 | $38–40 | Above buy-zone |
| SMID | ~$30.22 | ~$22–24 | Above buy-zone |
| ETON | ~$37.57 | ~$22–26 | Above buy-zone |

**Buy-zone triggered: DETEC.HE at €8.38–8.70 < €9.50 accumulate zone.** Promoted to QUEUED_HOT this run. §5 bench-promotion update memo written: memos/DETEC.HE-bench-2026-07-20.md. Adversarial red-team: CLEARED (12 failure modes; 2 flags embedded in Q=3). Grade B / CANDIDATE unchanged. Analyst count updated to 4 (from 3 in July 16 memo); consensus avg raised to €13.30 (from €12.18); gap to consensus now ~59% at €8.38. H1 2026 confirmed NOT yet published (August 6, 2026 — 17 days).

**5. Universe exploration audit:**
- Systematic enumeration (screen_eu.py, snapshot.py, EDINET API) remains blocked by proxy 403 — web search agents are the only working data source. This is a standing limitation carried from runs #37–45.
- Sector 17 (Semiconductor & electronics supply chain, 2nd pass, European geo lens) run this session: 23 names processed, 22 killed (15 new + 7 already-seen), 1 new QUEUED (CML.L 7/12).
- Sectors 18–19 active, sectors 0–4 THIN/EXHAUSTED, sectors 5–19 in rotation. No new sectors exhausted this run.

**6. Systemic fixes shipped this run:**
- Kill list company descriptions corrected for TPE.DE (PVA TePla, not Technotrans) and ELG.DE (Elmos Semiconductor, not ElringKlinger).
- WATCHLIST.md 6742.T price corrected ¥608 → ¥864 (buy-zone trigger removed).
- DETEC.HE promoted to QUEUED_HOT in WATCHLIST.md with §5 update memo.

---

### 2026-07-20 — §7 REFLECT run #48 (48%3=0)

**1. Data quality audit:**
- **STX.L.md REMS data defect corrected (run #48):** financials/STX.L.md previously claimed "REMS LOCK-IN + PROCESS + BRAND" as moat type. OPUS adversarial red-team (run #47, memos/STX.L-2026-07-20.md) confirmed ACCRUFeR has **NO REMS program**; NCE exclusivity expired July 2024; moat rests solely on a polymorph patent (Oct 2035) + prescriber habit + brand inertia. Moat type header corrected to "POLYMORPH PATENT + BRAND + INSTALLED-BASE (prescriber habit)." Correction notice block added to STX.L.md. This was the most significant KB data defect resolved this run.
- **MDP.TO Gleolan US rights corrected:** financials/MDP.TO.md §4 baseline revealed Gleolan US rights were **SURRENDERED March 2025** (NXDC agreement terminated) — triage moat claim was wrong. EMA Gleolan rights always with medac GmbH Germany. Real US moat = GRAFAPEX (treosulfan, 7-yr US orphan exclusivity ~Dec 2031). MDP.TO UNIVERSE.md and COVERAGE.md entries updated.
- **DXRX.L company name corrected:** Triage initially confused DXRX.L with "Diagnostyx plc" (formerly Yourgene Health). DXRX.L is **Diaceutics PLC** — a diagnostic commercialisation and data analytics platform (87% GM consistent with software/data model, NOT lab services). Correction added to financials/DXRX.L.md header.
- **SEDANA.ST price error corrected:** §4 baseline revealed actual price SEK 8.74 vs. triage assumption SEK 28-35. All SEDANA.ST calculations updated to use SEK 8.74. This was a ~3-4x price discrepancy.

**2. Bench re-pricing (2026-07-20):**
All bench prices confirmed by web search (trust ~ — snapshot.py remains blocked by Yahoo Finance 403). Key findings:

| Ticker | Last price | Buy-zone | Status |
|---|---|---|---|
| WINA | ~$385.44 | ≤ ~20–22x PE | Above buy-zone |
| CODA | ~$9.84–$10.00 | $8–10 | Approaching upper boundary |
| OFLX | ~$29.85 (~$308M) | ~$190–220M cap | Above buy-zone |
| EKF.L | ~25.4p | ≤~14-16p (~£80M cap) | Above buy-zone |
| 6823.T (Rion) | ~¥3,485 | ¥2,200–2,400 | Above buy-zone |
| 6742.T (Kyosan) | ~¥864 | ¥720 | Above buy-zone (prior ¥608 flag was WRONG — confirmed run #45) |
| **CGS.L** | **~260p** | **200-230p** | **⚠ APPROACHING (338p→260p; T-30-60p to trigger)** |
| EPEN.ST | ~156.20 SEK | 115-130 SEK | Above buy-zone |
| JOUT | ~$46.25 | $38–40 | Above buy-zone |
| SMID | ~$30.22 | ~$22–24 | Above buy-zone |
| ETON | ~$37.57 | ~$22–26 | Above buy-zone |
| **RX.V** | **~C$14.50 (~C$161M cap)** | **≤C$10-11/sh** | **DATA ERROR CORRECTED (prior C$7.50 was May 2023 stale data); now in extended zone — reassess asymmetry at corrected price** |
| 4549.T | ~¥3,050+ | a pullback to fair multiple | Above buy-zone (at 52-wk high area; not fresh-searched) |

**No buy-zone triggers this run.** CGS.L is approaching (T-30-60p). RX.V price corrected from stale 2023 data; buy-zone updated to ≤C$10-11/sh; now in extended zone at C$161M cap.

**WATCHLIST.md changes this run:**
- DETEC.HE removed — graduated to CANDIDATE Grade B in run #45; should not remain on bench.
- CGS.L price updated 338p → 260p with ⚠ APPROACHING flag.
- RX.V price corrected C$7.50 → C$14.50; buy-zone updated to ≤C$10-11/sh; extended zone noted.

**3. False negatives re-checked:**
- **PHO.OL (Photocure ASA, Oslo Bors):** COVERAGE_KILL confirmed valid. OPUS agent confirmed ≥4-7 Norwegian regional analysts (Pareto, DNB Markets, ABG Sundal Collier, Arctic, Carnegie confirmed). Photocure has a genuine REGULATORY MONOPOLY moat (sole FDA+EMA approved blue-light cystoscopy agent Hexvix/Cysview/HAL; 94% GM; patent to 2036; debt-free) — a quality kill, not a thesis kill. REVISIT ONLY IF analyst count drops to ≤2 through broker attrition AND cap corrects to ≤£30M.
- **RX.V (BioSyent, TSX-V):** WATCHLIST price corrected from stale May 2023 data (C$7.65 close = historical match). Current price ~C$14.50 (~C$161M cap) is in the extended zone; buy-zone ≤C$10-11/sh requires meaningful pullback. Quality thesis (62-quarter profit streak, 21% NI margin, net cash) intact; asymmetry not available at current price.

**4. Universe exploration audit:**
- Sector 10 (2nd pass, UK/European wholesale distributors): ~38 names processed; 0 new QUEUED. Structural thinness confirmed — PE consolidation removed most quality names, dominant distributors are private, over-covered, or >£1.5B cap. Sector 10 not yet EXHAUSTED (only 1 consecutive 0-new pass per ROUTINE.md rule).
- Deferred queue completions: SEDANA.ST → CANDIDATE Grade C (§5); MDP.TO → COVERAGE_KILL (§4); DXRX.L §4 complete + analyst count verified → §5 deferred.
- Systematic enumeration (screen_eu.py, screen_tw.py, EDINET API) remains blocked by proxy 403 — web search agents remain only working data source. Standing limitation.

**5. Systemic fixes shipped this run:**
- WATCHLIST.md DETEC.HE removed (graduated; no longer bench-eligible).
- WATCHLIST.md CGS.L price updated 338p → 260p with approach flag.
- WATCHLIST.md RX.V price corrected C$7.50-8.00 → C$14.50 with full correction note; buy-zone updated.
- STX.L.md moat type corrected from REMS_LOCK-IN to POLYMORPH PATENT + BRAND + INSTALLED-BASE; correction block added.
- UNIVERSE.md SEDANA.ST status QUEUED → CANDIDATE Grade C; MDP.TO QUEUED → COVERAGE_KILL.
- UNIVERSE.md DXRX.L entry: analyst count corrected from "4-5 borderline" to "2-3 confirmed PASSES gate"; §4 financial data added; status updated to §5 deferred run #49.

---

## 2026-07-21 — §7 REFLECT run #51 (51%3=0)

**Bench re-pricing (snapshot.py proxy-blocked; web-search fallback; all prices tagged ~):**

1. **4549.T Eiken Chemical (Japan FIT/LAMP)** — POTENTIAL BUY-ZONE. §7 REFLECT web-search confirms ¥2,145–2,354 range (2026-07-21 ~). Buy-zone is ¥2,000–2,400. **At ¥2,145–2,354 the stock is AT OR NEAR the lower boundary of the buy-zone** — first time in KB history 4549.T has traded inside its buy-zone. ⚑non-EN rule: yuho primary filing verification required before promoting to QUEUED_HOT. WATCHLIST updated. Note: price tagged ~ (web-search only); cannot tag ✓ until filing-anchored price confirmation.
2. **ELVA.TO Electrovaya** — Amazon warrant deal CONFIRMED FIRED July 15 2026. Stock C$15.89 at time of §7 check = **above buy-zone US$8.00-10.50 / C$11.00-14.50**. CATALYST → CANDIDATE. Re-entry thesis: pullback to C$11-13 / US$8-9 restores asymmetry if Amazon cumulative commitment US$280M + Jamestown factory ramp on-track. UNIVERSE.md and STATE.md updated.
3. **FAA.VI Fabasoft** — €11.80-12.00 range observed (below the €11.50-14.50 buy-zone lower end). More attractive entry than at memo write (€13.75). German E-Akte rollout catalyst unchanged.
4. **REC.L Record plc** — 54.11p (–37% from triage price ~86p). Watch for earnings catalyst confirmation.
5. **GENC Gencor Industries** — $15.18-15.20 range. IN BUY-ZONE ($12-16). Q3 FY2026 results expected August 2026 = hard-dated catalyst. NOTE: GENC WATCH memo (memos/GENC-2026-07-16.md) lacks the OPUS 12-mode adversarial red-team check. Deferred to run #52 after Q3 August 2026 data is available. Rationale: adversarial red-team on a name with a hard-dated Q3 catalyst is best run post-Q3 when the key load-bearing number (backlog → revenue conversion) can be verified directly.

**Sector 15 EXHAUSTED:**
- Sector 15 (Exchanges/data/niche financials) 3rd pass US geo lens (run #51): ~20 names processed; 18 killed; 2 PARKed (SAMG 5/12 Silvercrest UHNW RIA; HNNA 4/12 Hennessy Advisors mutual fund manager). **0 new QUEUED — 2nd consecutive 0-new pass → SECTOR 15 EXHAUSTED.** Structural finding: US exchange/clearing operators all >$7B cap; specialty insurance quality names $500M+ extended zone or reserve-concern-riddled; financial data providers absorbed by S&P/MSCI/FactSet; remaining RIAs/fund managers (SAMG, HNNA, GAMCO) have AUM-stickiness but floors are AUM-dependent not earnings-floor.
- REVIVE condition: new geo lens needed — Nordic/Scandinavian financial data niche (Oslo Bors/Nasdaq Stockholm micro-cap financial infrastructure) or ASX Australian securities infrastructure.

**False negatives re-checked:**
- **EAH.L (ECO Animal Health, AIM):** PARK valid confirmed. Generic tylvalosin erosion from China-based API manufacturers into EU markets = structural discount, not temporary mispricing. EV/EBITDA ~4x appears cheap but correctly prices eroding moat. Q≈1 disqualifies from Quality Bench. PARK 6/12 confirmed valid.
- **WATR.L (Water Intelligence, AIM):** PARK valid confirmed. 4 AIM analysts (knocked coverage axis to 0 in scoring), thin 5.6% net margin, no hard-dated catalyst — all three failure modes confirmed. Valid kill; not a false negative.

**Systemic fixes shipped this run:**
- WATCHLIST.md 4549.T price updated ¥3,050+ → ¥2,145–2,354 with POTENTIAL BUY-ZONE flag.
- UNIVERSE.md ELVA.TO status CATALYST → CANDIDATE; re-entry thesis noted.
- STATE.md Sector 15 passes 2→3; status ACTIVE→EXHAUSTED.
- STATE.md CATALYST count 1→0 (ELVA.TO graduated to CANDIDATE).
- UNIVERSE.md + STATE.md counter strings updated: 71→73 (SAMG PARK + HNNA PARK added); DXRX.L QUEUED→PARK corrected.
- KILL-LIST.md Sector 15 3rd pass US section added (18 kills, 2 PARKs).
- COVERAGE.md Sector 15 3rd pass US section added (EXHAUSTED status declared).

---

## 2026-07-21 — v4 TOOLING & METHODOLOGY UPGRADE (human-directed, out-of-band)

Applied by the operator after a diligence session, not by a REFLECT run:

1. **`tools/screen_tw.py` upgraded GM-only → full value-quality screen.** The TWSE `t187ap06_L_ci` endpoint exposes complete keyless fundamentals (revenue, gross profit, operating income, net income to parent, **EPS**), not just gross margin. The tool now outputs gross/operating/net margin, net income, EPS, derived share count, and — when a price feed is reachable — a live **P/E + market cap**. New flags `--min-om` and `--max-pe` (value gate). Price fetch is best-effort with query1→query2 fallback and **degrades to fundamentals-only when the feed is proxy-blocked** (so it still works in the cloud env). Taiwan is now our one non-English market with keyless primary-source fundamentals — rotate it in heavily.
2. **§3.5 PRICE-FEED FAILSAFE added.** Yahoo (snapshot.py price) is a known recurring proxy-block in the cloud. Rule: never tag a web-scraped price ✓ — mark it ~ (single-source), cap confidence, and a ~-price alone cannot support a CANDIDATE+ grade or Asymmetry-Gate pass. This closes the silent-✓ leak flagged in prior REVIEW entries.
3. **§1 DATA-REACHABILITY PRIORITY added.** US (SEC) and Taiwan (TWSE) are the two keyless, reachable, primary-source markets — give them the most enumeration runs. Japan/Korea are key-gated and often proxy-blocked → web-scout only until keys/feeds are wired.
4. **Geo override set to Taiwan** for the next run to exercise the upgraded screener end-to-end.

**Systemic fix still open:** restore a reachable live-price feed in the cloud env (the Asymmetry Gate depends on it); until then, foreign valuation runs at ~-trust.

---

## 2026-07-21 — v5 REFRAME (human-directed): unstick the trapped funnel

Operator diagnosis: recent runs (#45–52) had degraded to mostly 0-new + C/D/PARK grades. Root causes found: (a) the small-cap universe is largely swept (52 runs, sectors 2–5× each) — diminishing returns are structural; (b) the cloud env proxy-BLOCKS every non-SEC feed (Yahoo, EDINET, AND TWSE OpenAPI — confirmed run #50), so international §2A enumeration is dead and the routine is web-searching non-US names at ~-trust; (c) the near-term-2x asymmetry mandate systematically PARKED/benched the high-quality-but-fairly-valued compounders that are actually the best finds; (d) sonnet first-passes fabricating moats (STX.L "REMS", FAA.VI).

Changes applied to ROUTINE.md:
1. **§1 v5 PRIMARY DIRECTIVE** — the deliverable is now a DEEP quality-compounder BENCH with computed buy-zones, re-priced every run for dips; dip-catching > re-sweeping; a 0-new run that catches a bench dip is a SUCCESS.
2. **§3 cap ceiling relaxed** $1.5B → ~$8B for genuinely high-quality names (mid-cap quality was the biggest leak).
3. **§1 DATA-REACHABILITY corrected to v5** — only SEC/US works in the cloud; non-US = web-scout leads at ~-trust, C≤2; stop burning runs pretending §2A works abroad. Operator fix path documented (whitelist feeds / set keys).
4. **Anti-fabrication hard rule** — unconfirmed moat/number = ABSENT; a fabricated claim reaching a memo caps grade at PARK.

Systemic fix still open (operator-only): whitelist query1.finance.yahoo.com / api.edinet-fsa.go.jp / openapi.twse.com.tw and set EDINET_KEY/OPENDART_KEY to restore international reach + trustworthy prices.

---

## 2026-07-22 — v5.1 harvest-all-quality + retrieval upgrade (human-directed)

1. **KILLERS vs ROUTERS (§3):** Coverage, Cap, and Price are now ROUTERS, not killers — a durable-moat/clean/profitable business is ALWAYS captured (Quality Bench at minimum), never deleted for being well-covered, mid-cap, or already up. Fixes the leak (157 COVERAGE_KILL + 128 CAP_SOFT_KILL discarded quality). Only Sector/Moat-absent/Integrity/quality=0 kill.
2. **Every-run bench dip-catch (§7.4):** bench price-refresh + buy-zone promotion now runs EVERY run (cheap, price-only); catching a dip = a successful run even with 0 new names.
3. **Geo default US (§1):** international enumeration proxy-blocked in cloud → US-default lens; non-US = opportunistic web-scout only until feeds/keys wired.
4. **NEW retrieval engine `tools/fts.py` (§2A-FTS):** SEC full-text moat-language search (efts.sec.gov, keyless, cloud-reachable) — finds companies by the moat language in their own 10-Ks (sole supplier / only manufacturer / only FDA-cleared / …), ranked by # distinct phrases. Primary-source-grounded, fabrication-proof. Tested: 413 companies since 2024-06.
5. **§2-QUALITY orthogonal-lens rotation:** moat-language / supply-chain traversal / corporate-action / KB-internal thread-following (incl. reviving old quality kills) / first-principles hypotheses — rotate per run, logged in COVERAGE.md, to stop re-mining the same lists.

Live-ready (US-primary). Open operator item: whitelist query1.finance.yahoo.com / api.edinet-fsa.go.jp / openapi.twse.com.tw + set EDINET_KEY/OPENDART_KEY to restore international reach + trustworthy live prices.

---

## 2026-07-22 — v5.2 top-of-funnel retrieval fleet (human-directed)

Built + wired 5 new orthogonal idea-generation engines (all keyless, cloud-reachable, filing-grounded):
1. **tools/screen_quality.py** — ROE/net-margin enumerator that SEES FINANCIALS (banks/insurers/exchanges the GM screen can't) + flags ★ quiet-compounders (rev up ≥4/5yr). Sanity caps (nm/roe ≤60) drop revenue-tag artifacts. Tested: 310 names incl. PJT Partners, Ameriprise, Chipotle, Paychex, InterDigital.
2. **tools/fts.py --preset** — moat / pricing / lockin / scale / depend phrase archetypes (rotate per run). Tested: pricing→243 cos (MP Materials, Elanco, Valvoline).
3. **tools/fts.py --preset depend** — reverse supply-chain: filers naming a critical supplier → read to find the monopoly.
4. **quiet-compounder flag** — inside screen_quality (the ★).
5. **tools/insiders.py** — Form 4 open-market insider-buying CLUSTERS (2+ distinct buyers) from EDGAR daily index. Tested: works (scales with --max).

Wired into §2A (screen_quality alongside screen.py) and the §2-QUALITY lens rotation (fts presets, depend, insiders). All lenses logged in COVERAGE.md for diversity.

---

## 2026-07-21 — §7 REFLECT run #54 (54%3=0)

**1. Bench re-pricing (snapshot.py proxy-blocked; web-search fallback; all prices tagged ~):**

All 17 bench names re-priced as of 2026-07-21 via WebSearch agents. Full updated table:

| Ticker | Company | Last price (2026-07-21 ~) | Buy-zone | Status |
|--------|---------|--------------------------|----------|--------|
| WINA | Winmark | ~$385.44 (~$1.38B cap) | ≤ ~20–22x PE | Above buy-zone |
| CODA | Coda Octopus | ~$9.84–$10.00 (~$112.7M cap) | $8–10 / ≤ ~$107M cap | ⚠ APPROACHING upper boundary (cap $112.7M; trigger $107M; NOT triggered yet) |
| OFLX | Omega Flex | ~$29.85 (~$308M cap) | ~$190–220M cap | Above buy-zone |
| 4549.T | Eiken Chemical | ~¥2,271–2,423 | ¥2,000–2,400 | ⚠ POTENTIAL BUY-ZONE (within range; conflicting sources; EDINET proxy-blocked — cannot verify yuho before promotion; ⚑non-EN) |
| 6823.T | Rion | ~¥3,585 | ¥2,200–2,400 | Above buy-zone |
| EKF.L | EKF Diagnostics | ~25.4p (~£110.64M cap) | ≤~14-16p (~£80M cap) | Above buy-zone |
| 6742.T | Kyosan Electric | ~¥864 | ¥720 | Above buy-zone (prior ¥608 flag corrected in run #45) |
| CGS.L | Castings plc | ~260p | 200-230p | ⚠ APPROACHING (T-30-60p to trigger) |
| EPEN.ST | Ependion AB | ~SEK 97–99 | SEK 115-130 | ⚠ BELOW buy-zone lower boundary (SEK 97-99 < SEK 115); quality TBD ⚑non-EN — DO NOT promote until Swedish primary filing verified |
| JOUT | Johnson Outdoors | ~$44.78 | $38–40 | ⚠ APPROACHING (T-~$5 to trigger) |
| SMID | Smith-Midland | ~$30.22 | ~$22–24 | Above buy-zone |
| ETON | Eton Pharmaceuticals | ~$37.57 (~$1.03B cap) | ~$22–26 | Above buy-zone (near 52-wk high) |
| RX.V | BioSyent | ~C$14.50 (~C$158M cap) | ≤C$10-11/sh | Above buy-zone (extended zone) |
| MEDI.OL | Medistim ASA | ~NOK 226/sh (~NOK 4.15B / ~$395M USD cap) | ~$230-290M cap | Above buy-zone |
| SECARE.ST | Swedencare AB | ~SEK 26.35 (2026-06 ~) | TBD ⚑non-EN | Conditional bench — buy-zone TBD pending Swedish primary filing |
| NZX:SKL | Skellerup Holdings | ~NZD 6.13/sh (~NZD 1.19-1.28B / ~$715-770M USD) | ~NZD 350-450M cap | Extended zone (materially above buy-zone) |
| XRF.AX | XRF Scientific | ~A$2.28 (~A$323M cap) | A$1.40-1.65/sh | Above buy-zone |

**No buy-zone promotions this run.** 4549.T is potentially within its buy-zone range (¥2,271–2,423 vs. ¥2,000–2,400) but EDINET is proxy-blocked — ⚑non-EN rule requires yuho GM verification before any QUEUED_HOT promotion.

**2. Corrective edits made to WATCHLIST.md this run:**
- **EPEN.ST identity corrected:** Prior entry listed as "(Swedish small-cap — confirm name/business)." Confirmed = **Ependion AB** (Nasdaq Stockholm), industrial networking for rail/automation (Westermo brand, EN 50155 railway certification). Price has fallen from SEK 156.20 (run #42) to SEK 97-99 — now **BELOW** the buy-zone lower boundary (SEK 115). Quality still TBD ⚑non-EN — cannot promote without Swedish primary filing.
- **SECARE.ST identity corrected:** Prior entry listed as "Secare AB." Confirmed = **Swedencare AB** (pet health products — ProDen PlaqueOff, Duoxo, Vetri-Science brands). Buy-zone and quality score remain TBD ⚑non-EN.
- **NZX:SKL cap corrected:** Prior entry showed "~NZD $720M cap" (likely stale). Fresh data: ~NZD 6.13/sh × ~194M shares = NZD 1.19-1.28B cap (~$715-770M USD). Well above buy-zone of NZD 350-450M.
- **CODA approaching flag:** Added ⚠ note. Not triggered (cap $112.7M > $107M trigger).
- **4549.T potential buy-zone flag:** Added ⚠ POTENTIAL BUY-ZONE with EDINET-blocked caveat.
- **EPEN.ST below buy-zone flag:** Added ⚠ BELOW buy-zone lower boundary warning with quality-TBD caveat.
- Other prices refreshed: 6823.T, ETON, JOUT, RX.V, MEDI.OL, NZX:SKL, SECARE.ST.

**3. Data quality audit:**
- All 17 bench prices are web-search-sourced (trust ~), not verified via snapshot.py (Yahoo Finance 403). Non-EN filers (4549.T, 6823.T, 6742.T, EPEN.ST, SECARE.ST, NZX:SKL, MEDI.OL, RX.V, XRF.AX) carry additional trust caps.
- EDINET API remains proxy-blocked (403 Forbidden) — blocks Japanese filings verification. 4549.T cannot be promoted to QUEUED_HOT without restoring EDINET access or verifying GM from alternative filing source.
- Sector 17 shortlist §3-§4 triage this run confirmed the anti-fabrication rule working correctly: GSIT defense 45.7% SECTOR_KILL caught from Q4 financials; NVEC payout >100% NI flagged from SEC EDGAR reading; SVCO analyst count confirmed from multiple sources.

**4. False negatives re-checked:**
- **RELL (Richardson Electronics):** Re-checked. Confirmed NO_MOAT_KILL. Blended GM 31.9% (reported) fails the 45% GM gate decisively. The "sole-source magnetron/plasma etch RF" narrative is correct for a sub-segment, but the blended business includes substantial lower-margin distribution. The kill is on financials, not the moat narrative. No change needed.
- **INTT (inTEST Corporation):** Re-checked. Confirmed PARK 6/12. GM 45.5% barely passes the gate but multi-segment dilutes moat quality (Thermal Testing, Electronic Testing, Process Solutions all different moats). NI margin 2.4% + fwd P/E ~64x leaves no credible 2x path at current price. PARK stands.

**5. Universe exploration audit:**
- Sector 17 shortlist §3-§4 triage (5 names): all resolved (2 kills, 1 COVERAGE_KILL, 1 INTEGRITY_KILL, 1 PARK). Sector 17 now ACTIVE-SPARSE after 3 US passes + shortlist + 2 European passes with 3 consecutive 0-QUEUED outcomes. Next: 4th pass Japan secondary OEM.
- Sector 10 4th pass (Canadian TSX/DACH/spin-off lens): 3 names killed (GUD.TO SECTOR_ADJACENT_KILL, ADIG TRIPLE_KILL, OCTV SIZE_KILL). 0 new QUEUED. 1 consecutive 0-new pass after run #52 XRF find; need 2 for EXHAUSTED.
- No sectors moved to EXHAUSTED this run. Sector 10: 4 passes complete (1 consecutive 0-new). Sector 17: ACTIVE-SPARSE continuing.
- Systematic enumeration (screen_eu.py, screen_tw.py, EDINET API) remains proxy-blocked. US primary (SEC/fts.py) and WebSearch fallback remain the only working data paths.

**6. Systemic fixes shipped this run:**
- WATCHLIST.md: EPEN.ST, SECARE.ST, NZX:SKL corrected (identity/cap errors); 4549.T, CODA, EPEN.ST flags added; JOUT, MEDI.OL, RX.V, ETON, 6823.T prices refreshed.
- STATE.md: Total runs 53→54; Universe size 74→81; RELL PARK→NO_MOAT_KILL; +7 new universe entries (NVEC PARK, SVCO COVERAGE_KILL, GSIT INTEGRITY_KILL, INTT PARK, ADIG TRIPLE_KILL, OCTV SIZE_KILL, GUD.TO SECTOR_ADJACENT_KILL); ASX:XRF QUEUED→BENCH corrected; Sector 10 passes 3→4; Sector 17 status updated to reflect shortlist complete; run #54 log entry added; queue updated note added.
- COVERAGE.md: Sector 17 shortlist §3-§4 triage section added; Sector 10 4th pass section added.
- KILL-LIST.md: Run #54 entries added (NVEC, SVCO, GSIT, INTT, ADIG, OCTV, GUD.TO).

---

### 2026-07-27 — §7 REFLECT run #57 (57%3=0)

**1. Bench re-pricing (20 names — snapshot.py proxy-blocked; all prices via web search agents ~):**

| Ticker | Last price | Buy-zone | Status |
|--------|-----------|----------|--------|
| WINA | ~$385 | ≤~20-22x PE | Above zone |
| CODA | ~$9.84–$10.00 (~$112.7M cap) | $8-10 / ≤$107M cap | ⚠ APPROACHING (T-~$5.7M cap) |
| OFLX | ~$29.85 (~$308M cap) | ~$190-220M cap | Above zone |
| 4549.T | ~¥2,271–2,423 | ¥2,000–2,400 | ⚠ POTENTIAL BUY-ZONE (within range; EDINET proxy-blocked → cannot promote) |
| 6823.T | ~¥3,585 | ~¥2,200–2,400 | Above zone |
| EKF.L | ~25.4p (~£110.6M cap) | meaningful pullback | Above zone |
| 6742.T | ~¥864 | ~¥720 area | Above zone (corrected from prior ¥608 error) |
| CGS.L | ~316.8p | ~200-230p | Above zone (rebounded; ⚠ UNCERTAIN DATA — was 260p → 316.8p; approaching note removed) |
| ETON | ~$37.57 (~$1.03B cap) | ~$22-26 | Above zone |
| SMID | ~$30.22 | ~$22-24 | Above zone |
| EPEN.ST | ~SEK 97-99 | SEK 115-130 | BELOW zone; quality TBD ⚑non-EN — DO NOT promote |
| JOUT | ~$43.48 | ~$38-40 | ⚠ APPROACHING (T-~$3.48; drifting lower) |
| RX.V | ~C$14.50 (~C$158M cap) | ≤C$10-11 | Above zone |
| MEDI.OL | ~NOK 226 (~NOK 4.15B cap) | ~$230-290M USD cap | Above zone (far above) |
| SECARE.ST | ~SEK 26.35 | TBD ⚑non-EN | Quality/buy-zone not yet set |
| NZX:SKL | ~NZD 6.13 (~NZD 1.2B cap) | ~NZD 350-450M cap | Above zone |
| XRF.AX | ~A$2.28 (~A$323M cap) | A$1.40-1.65 | Above zone |
| JHD.L | ~143p | ~£200-250M cap | Above zone; RECENTLY APPROACHED (Jun 22 ~124p) |
| PHO.OL | ~NOK 64.1 (~NOK 1.74B cap) | NOK ≤50-55 | NEW BENCH — above zone |
| CUV.AX | ~A$10.24 (~A$516M cap) | A$6-8 | NEW BENCH — above zone |

No buy-zone triggers fired. CODA, JOUT most proximate to trigger; 4549.T within zone but EDINET proxy-blocked.

**2. False-negative re-check — pre-v5.1 COVERAGE_KILLs:**

Under v5.1, Cap/Coverage/Price are ROUTERS not KILLERS for Q≥4 names. Two run #47 COVERAGE_KILLs were Q=4 regulatory monopolies wrongly killed on coverage alone:

- **PHO.OL (Photocure ASA):** Sole FDA+EMA approved BLC photodiagnosis agent; 94% GM; debt-free; NOK 293.8M net cash; patent Dec 2036; 390+ US BLC systems; Q=4. COVERAGE_KILL (5-7 analysts) was CORRECT under pre-v5.1 rules; INCORRECT under v5.1. **REVIVED TO QUALITY BENCH.** Existing baseline financials/PHO.OL.md confirmed. Current price ~NOK 64.1 = above buy-zone NOK ≤50-55. Bench-monitor only.

- **CUV.AX (Clinuvel Pharmaceuticals):** Sole approved EPP drug (SCENESSE); FDA 2019 / EMA 2014; no therapeutic alternative; Q=4. Same correction. **REVIVED TO QUALITY BENCH.** §4 financial baseline not yet written (CUV.AX financials/CUV.AX.md = pending; write next run with ASX filing access). Current ~A$10.24 = above buy-zone A$6-8.

Additional false-negative check — run #56 CAP_SOFT_KILLs ATOSS Software SE and PSAN (PSI Software SE): Both killed on CAP_SOFT_KILL + COVERAGE_KILL. Under v5.1, coverage is a router for Q≥4. Both may be Q≥4 (German labor-law compliance HR SaaS; energy grid management software) but insufficient §4 data to confirm Q-score from web sources alone. **Flagged but NOT added to bench this run.** Require §4 Q-score verification from primary filing (German annual report / Geschäftsbericht) before any bench consideration.

**3. §4 financial baselines completed this run:**

- **ADMCM.HE (Admicom Oyj) — 9/12 QUEUED:** Helsinki First North Growth Market. FAS accounting. English Q1 2026 Interim Report used as primary source. Key confirmed: Revenue FY2025 EUR 37.7M (+6.1%); Q1 2026 EUR 9.5M; EBITDA 32.3% FY2025; EBIT 20.1%; NI EUR 5.31M; FCF EUR 7.88M; Net cash EUR 7.03M (Mar 31, 2026); NRR >106%; churn <6%; 96% recurring; guidance cut July 8: ARR 3-10%, revenue 2-6%. Price ~EUR 25 (~); 4 analysts; PT EUR 45-57. QUEUED (Catalyst=0; Finnish construction downturn → ARR Q1 2026 QoQ decline). REVISIT: Finnish construction PMI recovery + ARR returns to growth 2+ consecutive quarters. Baseline: financials/ADMCM.HE.md.

- **OMDA.OL (Omda AS) — 9/12 QUEUED:** Euronext Growth Oslo (EGM). IFRS. English filings available. VMS serial acquirer in Nordic healthcare ancillary clinical software (ProSang blood mgmt 100% market share Sweden+Denmark; Cytodose; Predicare/Aweria; Dermicus; Saab Public Safety Solutions acquired Jun 2026). Revenue NOK 496M (+16% FY2025); EBITDA 24% FY2025 (13%→24% margin expansion); 79-82% recurring; 2-4 analysts; NOK 59 PT (64% upside); EV/EBITDA ~7-9x vs VMS peers 15-25x. KEY DATA GAPS: net financial debt unconfirmed (IFRS 16 + earn-outs inflate nominal D/E to ~1485%; actual financial debt unknown); gross margin unconfirmed. QUEUED (Floor=1 due to balance sheet opacity; §5 requires annual report PDF to confirm financial debt and gross margin). Baseline: financials/OMDA.OL.md.

**4. 6858.T §5 gate re-check (H1 FY2026 earnings):**

H1 FY2026 earnings now out (released early vs. expected ~Jul 29). Revenue H1 ¥7,690M (+21.2% YoY) = BEAT. NI H1 ¥353M = SOFT (only 44% of ¥800M full-year guidance; requires ¥447M in H2). Management held FY2026 guidance unchanged — H2 back-weighting is expected for capital equipment companies (order backlog deliveries skew H2). Gate (a): SOFT PASS — guidance maintained but NI tracking soft; not a clean "on track." Gate (b): STILL BLOCKED — EDINET proxy-blocked; yuho gross margin cannot be verified. §5 requires BOTH gates. **Next milestone: Q3 FY2026 results (Oct/Nov 2026).**

**5. Sector 7 2nd pass:** 10 names; ALL killed; 0 new QUEUED; 1st consecutive 0-new pass. Structural finding: Sector 7 is thin because viable specialty ingredient/ag biologicals at $20-300M cap are either pre-commercial, distressed, or in adjacent sectors. See COVERAGE.md for full triage notes. Sector 7 remains ACTIVE (need 2 consecutive 0-new for EXHAUSTED).

**6. Systemic fixes shipped this run:**
- WATCHLIST.md: PHO.OL and CUV.AX added to Quality Bench (v5.1 false-negative revives); JHD.L price updated ~143p + RECENTLY APPROACHED BUY-ZONE note (Jun 22 ~124p inside zone).
- STATE.md: Total runs 55→57 (stale counter corrected); run #56 push status PENDING→OK; run #57 log entry added; deferred queue updated (6858.T gates updated; ADMCM.HE + OMDA.OL added as QUEUED); universe size 90→104.
- UNIVERSE.md: ADMCM.HE + OMDA.OL status updated to QUEUED with §4 written; PHO.OL + CUV.AX added as BENCH; 10 Sector 7 2nd pass kills added; universe size 92→104.
- COVERAGE.md: §7 REFLECT false-negative correction section added; Sector 7 2nd pass coverage notes added.
- KILL-LIST.md: Run #57 Sector 7 2nd pass kills appended (10 names).
- financials/OMDA.OL.md: Written this run (§4 baseline).
- financials/ADMCM.HE.md: Written this run (§4 baseline; confirmed as clean write from Q1 2026 English Interim Report).

---

## §7 REFLECT — Run #60 (2026-07-27)

**Mandatory REFLECT (60 % 3 = 0). Bench has 22 names (20 prior + IVU.DE + NSSC added this run).**

**1. Full bench re-price (all 22 names; all prices tagged ~ single-source web search):**

| Ticker | Prior price | New price ~ | Buy-zone | Status |
|--------|------------|-------------|---------|--------|
| WINA | $385.44 | $385.44 ~ | ≤~20-22x PE | Unchanged; above zone |
| CODA | ~$9.84-10.00 (~$112.7M) | ~$9.84-10.00 ~ | $8-10 / ≤$107M cap | Approaching upper bound; cap ~$112.7M — NOT triggered (need ≤$107M) |
| OFLX | ~$29.85 | ~$29.92 ~ | ~$190-220M cap | Stable; above zone |
| 4549.T | ~¥2,271-2,423 (zone) | ~¥3,010 ~ ⚑non-EN | ¥2,000-2,400 | ABOVE ZONE — recovered from prior zone proximity; POTENTIAL BUY-ZONE flag REMOVED |
| 6823.T | ~¥3,585 | ~¥3,585 ~ ⚑non-EN | ~¥2,200-2,400 | Above zone; unchanged |
| EKF.L | 25.40p | ~25.80p ~ | pullback / acceleration | Slightly higher; above zone |
| 6742.T | ~¥864 | ~¥864 ~ ⚑non-EN | ¥720 area | Above zone; unchanged |
| CGS.L | 260p | ~260p ~ | ~200-230p | Stable; T-30-60p from zone; not triggered |
| ETON | ~$42.32 | ~$42.32 ~ | ~$22-26 | Above zone; further from trigger |
| SMID | ~$30.22 | ~$30.28 ~ | ~$22-24 | Stable; above zone |
| EPEN.ST | ~SEK 97-99 | ~SEK 97-99 ⚑non-EN | SEK 115-130 | BELOW buy-zone lower boundary (SEK 97-99 < SEK 115); quality STILL TBD — DO NOT promote; bench agent run #60 returned stale Jul 17 data (SEK 156.20) — conflict noted; use Jul 21 confirmed price |
| JOUT | ~$45.96 | ~$45.96 ~ | ~$38-40 | Stable; T-$5.96 to trigger |
| RX.V | ~C$14.50 (~C$158M) | ~C$14.50 ~ | ≤C$10-11 | Above zone; unchanged |
| MEDI.OL | ~NOK 226 (~NOK 4.15B) | ~NOK 226 ~ | ~$230-290M USD cap | Above zone; far above |
| SECARE.ST | ~SEK 26.35 | ~SEK 22.05 ~ ⚑non-EN | TBD ⚑non-EN | Declining; down from SEK 26.35 Jun 2026; quality/buy-zone still TBD |
| NZX:SKL | ~NZD 6.13 (~NZD 1.19-1.28B) | ~NZD 5.43 (~NZD 1.05B) ~ | ~NZD 350-450M cap | Declining; above zone; T-NZD 600M+ from zone |
| XRF.AX | ~A$2.28 | ~A$2.12 ~ | A$1.40-1.65 | Drifting lower; T-A$0.47 from upper bound |
| JHD.L | ~128.44p | ~128.44p ~ | ~£200-250M cap | ⚠ APPROACHING — bench agent confirmed Jul 22 low ~119p (below prior Jun 22 low ~124p); recovered to 128.44p Jul 27; revenue stabilization required before promotion |
| PHO.OL | ~NOK 64.1 | ~NOK 64.1 ~ | NOK ≤50-55 | Above zone; unchanged |
| CUV.AX | ~A$10.24 | ~A$10.24 ~ | A$6-8 | Above zone; unchanged |
| IVU.DE | NEW | ~€20 (~€346M cap) ~ | ≤~€200-250M cap | NEW BENCH — above zone (COVERAGE_KILL v5.0 → v5.1 false-negative fix) |
| NSSC | NEW | ~$36.09 (~$1.44B cap) ~ | ~$22-26 | NEW BENCH — above zone (forwarded Sector 11 v5.0 → v5.1 false-negative fix) |

**No buy-zone triggers fired this run.** CODA and EPEN.ST most proximate. JHD.L approaching (119p dip confirmed Jul 22 — now recovered).

**2. v5.1 False-negative audit — run #60:**

Under v5.1, Coverage and Cap are ROUTERS not KILLERS for Q≥4. Two names from prior runs were incorrectly killed/routed:

- **IVU.DE (IVU Traffic Technologies, Germany):** Mission-critical transit operations SaaS (IVU.suite: vehicle scheduling/dispatching/fleet/ticketing for public transit authorities). Embedded in daily government operations; decade-long government contracts; near-monopoly in DACH markets. FY2025: GP €121.5M / Rev €149.7M = **81% GM**. FY2026 EBIT guidance raised to €22M. 6 analysts (all Buy; consensus PT ~€26-27). COVERAGE_KILL under v5.0 = FALSE-NEGATIVE under v5.1 (Q4 defensible; mission-critical SaaS with government switching costs). Current price ~€20 (~€346M cap) = above buy-zone (≤~€200-250M cap). **ADDED TO QUALITY BENCH.**

- **NSSC (Napco Security Technologies, Nasdaq):** Security electronics + StarLink cellular cloud access control subscription. **91% recurring services GM**; recurring revenue crossing 50% of total; $115M net cash, zero debt; installed-base flywheel. ~40M shares. Record revenues. Forwarded to Sector 11 3rd pass worklist under v5.0 (never formally bench-listed). Under v5.1, this is a clear Q4 BENCH name. Current price ~$36.09 (~$1.44B cap) = above buy-zone (~$22-26). **ADDED TO QUALITY BENCH.**

**3. Sector 9 2nd pass US geo lens results (run #60):**

~23 US environmental/waste/water names processed. 21 kills (all §3). No new QUEUED. Structural: US env/water at $20-300M cap is structurally thin — development-stage clean-tech (SCWO, PCT, AREC, CLIR, AERC, PYRGF) dominates the small-cap tier; scaled operators (ERII ~$2.4B, NVRI ~$1.2B, OPAL) are SIZE_KILL; micro-cap names (TOMZ, BCHT, QRHC, OBCI, EVI, GURE) lack durable moat. Two near-misses:
- **PESI** (§4 PARK): US environmental services; moat present but GM_THIN (~28-35%, fails ≥45% gate). Cannot add to bench.
- **CWCO** (Consolidated Water Co.): Caribbean water concession + desalination moat; possible real moat; but EXTENDED ZONE; deferred to Sector 9 3rd pass §4 (requires confirmation of moat durability and price-path to ≥2x from primary filing; concession expiry dates critical).

2nd consecutive 0-new pass (Nordic run #28 = 1st; US run #60 = 2nd) → **Sector 9 US geo EXHAUSTED.** Next: UK AIM/ASX environmental/water 3rd pass.

**4. Systemic fixes shipped this run:**
- WATCHLIST.md: IVU.DE + NSSC added (22 names total); 4549.T POTENTIAL BUY-ZONE flag removed (¥3,010 above zone); SECARE.ST updated SEK 22.05; NZX:SKL updated NZD 5.43; JHD.L note updated (Jul 22 low 119p confirmed); EPEN.ST stale data note added; EKF.L 25.80p; SMID $30.28; OFLX $29.92.
- STATE.md: Total runs 59→60; universe 105→125; Sector 9 row updated (2 passes, ACTIVE-THIN); run #60 queue entry + log row added; Sector 6 row updated (IVU.DE false-neg fix noted); Next/Last sector updated.
- UNIVERSE.md: Universe size 105→125; rotation cursor updated; 20 new names added.
- COVERAGE.md: Sector 9 2nd pass US section added.
- KILL-LIST.md: Run #60 Sector 9 2nd pass US kills appended (21 names).

---

## §7 REFLECT — Run #63 (2026-07-27)

**Mandatory REFLECT (63 % 3 = 0). Bench now has 26 names (25 prior + TSTL.L added this run).**

**1. Full bench re-price (all 25 pre-existing entries; all prices tagged ~; TSTL.L is new, price TBD):**

| Ticker | New price ~ | Buy-zone | Status |
|--------|------------|---------|--------|
| WINA | ~$386 | ≤~20-22x PE | Stable; above zone |
| CODA | ~$11.78 (~$132M cap) | $8-10 / ≤$107M cap | ↑+20% from $9.84; ABOVE zone; approaching-note REMOVED |
| OFLX | ~$29.75 | ~$190-220M cap | Stable; above zone |
| 4549.T | ~¥2,354 | ¥2,000-2,400 | ⚠ **IN BUY-ZONE** — EDINET proxy-blocked; §5 still blocked pending proxy fix |
| 6823.T | ~¥3,453 | ~¥2,200-2,400 | Slight ↓; above zone |
| ETON | ~$42.32 | ~$22-26 | Stable; above zone |
| SMID | ~$30.28 | ~$22-24 | Stable; above zone |
| EPEN.ST | ~SEK 97-99 | SEK 115-130 | BELOW zone lower boundary (SEK 97-99 < SEK 115); BUT quality not confirmed → DO NOT promote; monitor |
| JOUT | ~$44.78 | ~$38-40 | Slightly below zone upper bound; T-$4.78 to trigger |
| RX.V | ~C$14.50 | ≤C$10-11 | Above zone |
| MEDI.OL | ~NOK 226 | ~$230-290M USD cap | Above zone |
| CGS.L | ~260p | ~200-230p | Stable; T-30-60p from zone |
| 6742.T | ~¥864 | ~¥720 | Above zone |
| SECARE.ST | ~SEK 22.05 | TBD ⚑non-EN | Declining; quality/buy-zone still TBD pending Swedish filing |
| NZX:SKL | ~NZD 5.43 (~NZD 1.05B) | ~NZD 350-450M cap | Declining; well above zone |
| XRF.AX | ~A$2.28 | A$1.40-1.65 | T-A$0.63 from upper bound; above zone |
| IVU.DE | ~€18-20 (~€310-345M cap) | ≤~€200-250M cap | ⚠ APPROACHING (price ≤€20 but cap still ~€310-345M above ≤€250M trigger; NOT fired) |
| NSSC | ~$35-37 | ~$22-26 | Stable; well above zone |
| JHD.L | ~128.44p | ~£200-250M cap | ⚠ APPROACHING (Jul 22 low ~119p confirmed below zone; recovered; revenue stabilization condition NOT met) |
| PHO.OL | ~NOK 59.2 | ≤NOK 50-55 | ⚠ APPROACHING (T-NOK 4-9 from trigger; declining from NOK 64.1) |
| CUV.AX | ~A$9.13-10.20 | A$6-8 | Slight pullback; above zone |
| OMDA.OL | ~NOK 39 | ≤NOK 35-40 | ⚠ **IN/AT BUY-ZONE** — annual report PDF 403-blocked; §5 still blocked pending proxy fix |
| CER.L | ~1,070p (~£315.9M cap) | ~850-900p / ~£250-265M cap | Above zone; §3.5 COMPLETE this run |
| TSTL.L | ⚠ PRICE CHECK REQUIRED | TBD | NEW — added this run; last known ~£215-220M cap from UNIVERSE; buy-zone TBD |

**Buy-zone triggers active:** 4549.T IN zone; OMDA.OL IN/AT zone. Both blocked by proxy (EDINET / annual report PDF). No bench promotions this run. PHO.OL and IVU.DE approaching.

**2. v5.1 false-negative audit — run #63:**

- **TSTL.L (Tristel plc, AIM UK):** Medical device decontamination consumables (chlorine dioxide — Tristel Trio, Tristel Sporicidal). CONSUMABLE + REGULATORY moat: each device type requires specific CE/MHRA regulatory approval; hospital infection-control protocols specify Tristel by brand → formulary lock-in; hospitals repurchase on consumable cycle. 81% GM (confirmed UNIVERSE.md). Profitable; net cash. US FDA 510(k) in progress (binary catalyst for US market entry). 6 AIM analysts. **Killed run #44 under pre-v5.1 COVERAGE_KILL (6 analysts)**. Under v5.1, 6 analysts routes to bench for Q≥4 names (not KILLED). With 81% GM + regulatory+consumable moat → Q4 defensible. **ADDED TO QUALITY BENCH run #63.** Buy-zone TBD — price-check required next bench agent run; last known cap ~£215-220M.

**3. CER.L §3.5 completion (run #63 key deliverable):**

§3.5 agent completed with primary filing data. Key confirmed findings:
- **Net cash £34.4M** ✓ (FY2025 year-end; zero bank debt)
- **FCF £10.9M** ~ (OCF £13.2M − capex £2.3M; 24% FCF margin)
- **Dilution negligible** ✓ (~0.2% options; all treasury-settled; no new equity issuances; Louis Hall Jun 2025 sale was secondary, no new shares)
- **Revenue model CRITICAL REVISION:** NOT pure SaaS. ~35% truly recurring ARR (£19.1M support/maintenance/cloud hosting); ~65% is UPFRONT licence recognition at customer go-live (not rateable). The Omantel £42.5M deal will generate one large licence recognition event on implementation completion (expected H2 FY2026), not a spread.
- **H1 FY2026 revenue £18.0M** (-14% YoY) — confirmed timing headwind, not demand collapse; Omantel go-live expected H2.
- **§4 score revised 8/12** (from provisional 9/12): Business quality 2→1 (35% recurring confirmed vs. implied 100%; revenue lumpy; FCF conversion 47%). Floor quality remains 2/2 (confirmed net cash + FCF).
- **Buy-zone confirmed: ~850-900p / ~£250-265M cap**. §5 eligible on next dip to ≤900p.

**4. NTECH.ST §5 Opus adversarial pass (this run's red-team result):**

Opus correctly identified that Nordtech's dental portfolio (Opus Dental, Opus Prodentus) was FABRICATED — Opus Dental is owned by Planmeca Oy (Helsinki-based dental equipment manufacturer), NOT by Nordtech. Nordtech's actual business (InfoMentor education, Thea Commerce, FinMeas, Reqtest, Benchmarking Alliance) has no dental asset. §4 moat claim rested entirely on this fabricated asset. PARK Grade D (Q2/F2/R2/C2). Confirms Opus adversarial pass is working correctly — Sonnet first-pass can invent subsidiary claims that Opus red-team catches.

**5. Sector 5 TIC 1st pass (run #63) — summary:**

Agent returned 25 names. Of these, the vast majority were ALREADY IN SEEN SET from prior incidental passes (killed in runs 2026-07-16 through 2026-07-27 during other sector sweeps). **New names triaged this run:**
- **RCDO (Ricardo PLC, LSE)** — SECTOR_KILL: Defence operating segment (engineering testing for defence OEMs). ~£265M cap.
- **TIC (TIC Solutions, NYSE)** — PARK: Post-IPO (Feb 2025, formed from NV5+Acuren merger); broad-based industrial NDT at $2.2B revenue guidance scale; not narrow-niche moat; integration execution risk.
- **MEG (Montrose Environmental Group, NYSE)** — PARK: Environmental testing roll-up; PFAS + lab accreditation angle interesting but GM/margin structure unverified; analyst count unknown; revisit Sector 5 2nd pass.
- **FORM (FormFactor, Nasdaq)** — SIZE_ROUTER: ~$3.12B cap, above extended zone; probe card niche moat real (35% global market share, HBM4 tailwind, IP-protected designs) but price extended at current cap. Note as quality reference; not bench-eligible until meaningful cap pullback.

**Already-confirmed SEEN names re-encountered (no new entries required):** TRNS, MG, MLAB, CLB, NEOG, VREX, TISI, AEHR, COHU, COTN, JDG.L (PARK 5/12), PRV.L, EKF.L (CANDIDATE 7/12 in UNIVERSE), NCYT.L, JFS.L (James Fisher, defense → SECTOR_KILL already logged). CODA on bench; defense segment ~10% minority; primary business civilian marine inspection; KEEP on bench.

**6. Systemic fixes shipped this run:**
- WATCHLIST.md: All 25 prior entries re-priced; TSTL.L added (#26); CER.L entry updated (§3.5 complete, quality 8/12, net cash £34.4M ✓, 35% recurring confirmed); JHD.L + PHO.OL last-verified dates updated to 2026-07-27; OMDA.OL + CER.L approach/zone notes current.
- financials/CER.L.md: Full §3.5 completion written — net cash, FCF, dilution, capex, revenue model (35% recurring clarification), H1 FY2026 data, governance notes, revised §4 8/12.
- KILL-LIST.md: RCDO (SECTOR_KILL), TIC (PARK), MEG (PARK), FORM (SIZE_ROUTER) appended — Sector 5 1st pass new names.
- COVERAGE.md: Sector 5 1st pass coverage notes added.
- UNIVERSE.md: Sector 5 names (RCDO, TIC, MEG, FORM) added; universe size updated.
- STATE.md: Total runs 62→63; Sector 5 pass count 0→1; deferred queue updated (4549.T + OMDA.OL IN zone but blocked; CER.L §3.5 complete; TSTL.L new bench); run #63 log entry added.

---

## §7 REFLECT — Run #66 (2026-07-27)

**Mandatory REFLECT (66 % 3 = 0). Bench has 27 names (26 prior + NSSC added run #65). This REFLECT: full bench re-price, data quality audit, universe exploration audit, false-negative re-checks.**

**1. Full bench re-price (all 27 names; all prices tagged ~ single-source web search; snapshot.py proxy-blocked):**

| Ticker | Last price ~ | Buy-zone | Status |
|--------|-------------|---------|--------|
| WINA | ~$388 | ≤~20-22x PE | Above zone; stable |
| CODA | ~$9.84-10.00 (~$113M cap) | $8-10 / ≤$107M cap | ⚠ APPROACHING (T-~$6M cap; not triggered) |
| OFLX | ~$29.75 | ~$190-220M cap | Above zone; stable |
| 4549.T | ~¥2,907 ⚑non-EN | ¥2,000-2,400 | **ABOVE ZONE — IN-BUY-ZONE FLAG CLEARED** (recovered +24% from ¥2,354; EDINET blocked → cannot promote until yuho GM confirmed) |
| 6823.T | ~¥3,585 ⚑non-EN | ~¥2,200-2,400 | Above zone |
| EKF.L | ~25-27p | meaningful pullback | Above zone; stable |
| 6742.T | ~¥864 ⚑non-EN | ~¥720 | Above zone |
| CGS.L | ⚠ ~338p (LSE Jun 29) vs ~260p (prior) | ~200-230p | ⚠ CONFLICTING DATA — 338p used as most authoritative; T-108-138p from zone |
| ETON | ~$36.63 | ~$22-26 | ↓ from $42.32; still well above zone |
| SMID | ~$30.28 | ~$22-24 | Above zone |
| EPEN.ST | ~SEK 156.20 ⚑non-EN | SEK 115-130 | Above zone; below-zone flag CLEARED (confirmed recovered) |
| JOUT | ~$45.96 | ~$38-40 | Above zone; T-$5.96 |
| RX.V | ~C$14.65 | ≤C$10-11 | Above zone |
| MEDI.OL | ~NOK 226-234 | ~$230-290M USD cap | Above zone |
| SECARE.ST | ~SEK 22.05 ⚑non-EN | TBD ⚑non-EN | Stable/declining; quality/buy-zone still TBD |
| NZX:SKL | ~NZD 5.23-5.43 | ~NZD 350-450M cap | Declining; well above zone |
| XRF.AX | ~A$1.77 | A$1.40-1.65 | ⚠ **APPROACHING** — ↓22% from A$2.28; T-A$0.12 to upper bound A$1.65; monitor closely |
| IVU.DE | ~€20 (~€310-345M cap) | ≤~€200-250M cap | ⚠ APPROACHING (price ≤€20 but cap still ~€310-345M above ≤€250M trigger; NOT fired) |
| NSSC | ~$36.67 | ~$22-26 | Above zone; stable |
| JHD.L | ~119-128p | ~£200-250M cap (~49-61p) | Above zone; prior "approaching" note was data error (shares 408M; zone is 49-61p, not ~130p) |
| PHO.OL | ~NOK 58.80 | ≤NOK 50-55 | ⚠ APPROACHING (T-NOK ~4-9; declining) |
| CUV.AX | ~A$10.24 | A$6-8 | Above zone |
| OMDA.OL | ~NOK 36.20 | ≤NOK 35-40 | ⚠ **IN BUY-ZONE** — §5 BLOCKED (annual report PDF 403) |
| CER.L | ~1,070p | ~850-900p / ~£250-265M cap | Above zone; EV ~£281.5M; §3.5 COMPLETE; §5 eligible at ≤900p |
| TSTL.L | ~402.5p | ~220-260p / ~£130-155M cap | Above zone; FDA 510(k) catalyst pending |
| IVU.DE | (see above) | | |
| PHO.OL | (see above) | | |

**No buy-zone promotions triggered.** XRF.AX approaching (T-A$0.12); OMDA.OL IN zone (blocked); 4549.T recovered above zone (flag cleared). Three names approaching trigger: XRF.AX (closest), PHO.OL, CODA (by cap).

**2. Data quality audit:**

Sampled the two most recently written financial baselines:

- **financials/NSSC.md (run #65):** Properly formatted. All figures tagged ~ (web aggregator; primary 10-K not read this run). Limitations correctly disclosed ("All figures ~ single-source web aggregator; primary 10-K not directly read this run"). C=2 cap correctly applied. Buy-zone $22-26 consistent with Q4/F4 assessment. No defects found beyond standing proxy-block limitation.

- **financials/CLX.md (run #65):** Well-structured. Correct two-tier trust tagging: FY2025 data ✓ (primary filing-anchored), FY2026 data ~ (unaudited RNS only). Internal consistency check passes (FY2025: £18,386K rev − £4,623K COGS = £13,763K GP ✓). Open questions clearly flagged. C=2 correctly applied for FY2026 unaudited data. No defects found.

Standing limitation unchanged since run #42: snapshot.py (Yahoo Finance), SEC EDGAR FTS (efts.sec.gov), EDINET Japan, TWSE Taiwan all proxy-blocked (403/no-price). All bench prices and non-US financials from web-search agents only (~trust). No improvement in data infrastructure this run.

**3. Universe exploration audit:**

Sector 19 3rd pass (US specialty healthcare services & niche pharma) launched this run via background search agent. Expanded search covered ~10 candidate names:

- **CLSD (Clearside Biomedical):** XIPERE suprachoroidal eye-drug platform — filed Chapter 11 Nov 2025 → **INTEGRITY_KILL / VIABILITY**
- **MODV (ModivCare):** Largest US NEMT broker — filed Chapter 11 Aug 2025 → **INTEGRITY_KILL / VIABILITY**
- **QIPT (Quipt Home Medical):** Home DME services — privatized Dec 2025 → **NOT_PUBLIC_KILL**
- **RCEL (AVITA Medical):** RECELL burn wound cell therapy (sole FDA-approved regenerative for burns) — EPS TTM -$1.74; NOT PROFITABLE → **NOT_YET_PROFITABLE_KILL** (Q1 2026 revenue $19.3M; $80-85M FY2026 guidance; cap ~$86-155M conflicting; potential re-check when/if profitable)
- **GERN (Geron Corp):** RYTELO first-in-class telomerase inhibitor for MDS — FY2025 revenue $184M, FY2026 guidance $220-240M but operating expenses $230-240M → NOT PROFITABLE in 2026 → **NOT_YET_PROFITABLE_KILL** (also: revenue scale $180-240M → approaching SIZE threshold for micro-cap focus)
- **VRCA (Verrica Pharma):** YCANTH sole FDA-approved for molluscum contagiosum — FY2025 revenue $35.6M; Q1 2026 revenue $5.0M (+25% YoY); cap ~$86-120M (conflicting); "cutting losses" per results → likely still unprofitable → **NOT_YET_PROFITABLE_KILL** (monitor: revenue growing fast; if profitable in FY2026 with sustained margin, revisit at Sector 19 4th pass)
- **CPIX (Cumberland Pharma):** Multi-product specialty pharma — $44.5M FY2025 revenue (+18%); multiple products (no sole-approved regulatory moat); GM unknown → **MOAT_SOFT_KILL** (diversified portfolio, not regulatory monopoly moat)

Structural finding confirmed: US specialty pharma at $20-300M cap / profitable threshold is structurally sparse. Named regulatory moats (sole-approved = genuine moat) tend to be either (a) pre-profitable → kills on earnings gate or (b) scaled beyond micro-cap once product launches. The Sector 19 US sweet spot is empty for this criterion.

Background search agent did not complete full triage of YMAB (Y-mAbs) and ARQT (Arcutis) before this REFLECT entry was written. Both unlikely to qualify: YMAB was likely unprofitable in 2026; ARQT (ZORYVE) competes against many dermatology alternatives (not sole-approved). Sector 19 3rd pass: **0 new QUEUED** (1st consecutive 0-new pass on US geo lens). Sector 19 still ACTIVE (need 2 consecutive 0-new for EXHAUSTED).

**4. False-negative re-checks:**

- **LOAD.L (Crestchic plc, AIM, ~£112M):** SURFACED UNTRIAGED in KILL-LIST. Load bank testing equipment for generator/UPS acceptance testing. Niche capital equipment; serves data centres, utilities, defence, offshore. Moat: sole-product position in portable load banks. BUT: (a) capital equipment, not consumable → lower quality/GM expected; (b) no data on GM; (c) ~£112M cap with unknown analyst coverage; (d) listed as "UNTRIAGED" — needs formal §3 triage next run. Preliminary assessment: likely Q≈2-3 (capital equipment cycle, not recurring consumable); needs data verification before bench/kill decision. **ADD TO §3 TRIAGE QUEUE next run.**

- **TFW.L (FW Thorpe, AIM ~£364M):** SIZE_KILL. KILL-LIST note: "revisit if cap corrects below £250M + analyst count ≤3." Current cap ~£364M = above £250M threshold. SIZE_KILL stands. Not a false negative at current price. No change.

**5. Corrective edits shipped this run:**

- WATCHLIST.md: 4549.T IN-BUY-ZONE flag CLEARED (price updated ¥2,354→¥2,907; above zone); XRF.AX updated A$2.28→A$1.77 + APPROACHING flag added; CGS.L updated to ⚠ CONFLICTING DATA 338p (LSE authoritative) vs 260p (prior); EPEN.ST updated SEK 138-156→SEK 156.20 (precise; above-zone confirmed); PHO.OL updated NOK 59.2→NOK 58.80; OMDA.OL updated NOK 37.90→NOK 36.20 (IN BUY-ZONE confirmed).
- STATE.md: Total runs 65→66; Sector 19 pass count 2→3 (1st consecutive 0-new pass US geo lens); run #66 log entry added; new kills (CLSD, MODV, QIPT, RCEL, GERN, VRCA, CPIX) added to universe.
- KILL-LIST.md: Sector 19 3rd pass US kills added (7 names).
- UNIVERSE.md: Universe size updated; 7 new kills added.

---

## §7 REFLECT — Run #69 (2026-07-27)

**Run #69 — §7 REFLECT mandatory (69%3=0).**

### 1. Data Quality Audit

**NSSC.md (Napco Security Technologies):**
- All figures correctly tagged ~ (single-source web aggregator; primary 10-K not read this run)
- C=2 cap applied correctly per v5.1 rules
- Services GM ~91% ✓; net cash $115M ✓; recurring rev >50% ✓; FCF $51.4M ✓
- Data integrity: PASS — appropriate uncertainty tags throughout; no fabricated claims
- Open item: FY2026 annual results (June 2026) not yet filed; update when available

**OMDA.OL.md (Omda AS):**
- GM ~63.3% correctly tagged as single-source Q2 2025 (Investing.com earnings call snippet) with ⚠ unconfirmed from primary filing
- Net financial debt ~NOK 190-260M correctly tagged ? (analyst estimate)
- FCF NOK 70-95M correctly tagged as estimated, unconfirmed
- C cap C≤2 correctly applied (Euronext Growth Oslo; IFRS English filings; balance sheet complexity unresolved)
- Data integrity: PASS — all key gaps explicitly flagged; §5 block maintained until annual report primary filing accessible

### 2. Universe Exploration Audit

**§2B false-negative re-check:** Sector 19 specialty pharma (Canadian/Nordic) cross-sector sweep surfaced HLS Therapeutics (TSX: HLS). Triaged and PARK'd MOAT_SOFT 5/12. No other missed names identified in this pass.

**Sector status:** Sector 19 EXHAUSTED after 4 passes confirmed. All active sectors reviewed and cursor maintained.

**MEG→ONT rename:** MEG ticker identified as renamed to ONT (Onterris Inc) effective May 4, 2026. Noted in UNIVERSE.md, KILL-LIST.md, and STATE.md inline lists.

### 3. False-Negative Re-checks

**VGO.WSE kill reason error corrected:**
- Error: STATE.md Sector 18 description stated "VGO.WSE PARK (GM ~35% fails gate)" — this was incorrect
- Correction: VGO.WSE GM confirmed ~49-50% (from WSE press release/Euronext Poland search snippets corroborating WSE annual filing data). The actual kill reason is NOT_YET_PROFITABLE: FY2025 net loss PLN -6.9M (worsening from FY2024 PLN -6.3M); NM and ROE both negative/below threshold
- KILL-LIST.md §3.5 VGO.WSE row updated: FY2025 NI PLN -6.9M confirmed (corrected from prior FY2024 -6.3M)
- STATE.md Sector 18 row corrected to: "VGO.WSE PARK (NM/ROE fail; GM ~49-50% confirmed; FY2025 NI PLN -6.9M NOT_YET_PROFITABLE)"
- Impact assessment: VGO.WSE kill remains valid (not a false negative — loss-making with worsening NI); but the kill reason in the record was factually wrong. Corrected.

**NORDH.OL:** Re-confirmed INTEGRITY_KILL (from prior run); not a false negative.

**HLS.TSX:** New name surfaced by §2B cross-sector scan — PARK 5/12 MOAT_SOFT (correct kill; Clozaril/Vascepa generic erosion + CSAN Pronto unverified + GM unknown).

### 4. Bench Re-price (run #69)

| Ticker | Prior | Updated | Status |
|--------|-------|---------|--------|
| PHO.OL | NOK 64.1 (APPROACHING removed) | NOK 58.80 | ⚠ APPROACHING RESTORED — T-NOK 3.80; Q2 earnings Jul 29 |
| ETON | $36.63 | $29.44 | ⚠ APPROACHING — T-$3.44 from ≤$26 trigger; declining |
| IVU.DE | €22.70 (~€402M) | €20.00 (~€354M) | ⚠ APPROACHING RESTORED — cap declining; T-€104M from ≤€250M |
| ALRIB.PA | TBD (not priced) | €10/sh (~€51M) | First price set; buy-zone ≤€5-6/sh; no approaching flag |
| CODA | $10.00 (Jul 14 data) | $10.00 (Jul 27 refresh) | ⚠ APPROACHING — price flat; cap $112.5M vs ≤$107M trigger |

**No promotions triggered this run.** PHO.OL closest at T-NOK 3.80 from ≤55 trigger — Q2 earnings Jul 29 is a near-term catalyst that could push price below zone. Monitor at next run (run #70).

### 5. Corrective Edits Summary

Files edited this run:
- **WATCHLIST.md**: ETON $29.44 ⚠APPROACHING; PHO.OL NOK 58.80 ⚠APPROACHING; IVU.DE €20.00 ⚠APPROACHING; ALRIB.PA first price €10; CODA date refresh 2026-07-27
- **KILL-LIST.md**: VGO.WSE FY2025 NI updated PLN -6.9M; HLS.TSX PARK run #69 section appended
- **UNIVERSE.md**: Size 223→224; HLS.TSX PARK added to inline list and universe map; MEG→ONT rename noted
- **STATE.md**: Total runs 68→69; Universe size 223→224; Sector 18 VGO.WSE kill reason corrected; HLS.TSX added to inline list; queue note + run #69 log row appended
- **COVERAGE.md**: Run #69 coverage notes appended

---

## §7 REFLECT — Run #72 (2026-07-27)

**Run #72 — §7 REFLECT mandatory (72%3=0). Bench has 33 names. Sector 18 4th pass US geo lens this run.**

### 1. Full Bench Re-Price (all 33 names — all prices ~ web-search; snapshot.py proxy-blocked)

All prices updated via web-search sub-agents. Key movements and corrections:

| Ticker | Prior price | New price ~ | Buy-zone | Status |
|--------|------------|-------------|---------|--------|
| WINA | ~$373 | ~$385-388 (Jul 17) → ~$373 (Jul 27 ~) | ≤~20-22x PE | Stable; above zone |
| CODA | $10.00 ($112.5M cap) | ~$10.00 (~$112.5M cap) | $8-10 / ≤$107M cap | ⚠ APPROACHING — T-$5.5M from ≤$107M cap trigger; price flat since run #68 |
| OFLX | $29.75 | $30.28 (Jul 22) | ~$190-220M cap | Minor ↑; above zone |
| 4549.T | ~¥2,907 | ~¥2,600 range (conflicting ¥2,271-2,907) | ¥2,000-2,400 | Above zone (multiple sources conflicting; leave at ¥2,907 proxy) |
| **6823.T** | **~¥3,585 (DATA ERROR)** | **~¥2,316** | ¥2,200-2,400 | **⚠ DATA ERROR CORRECTED → IN BUY-ZONE** (¥3,585 above 52-wk high of ¥2,918 = impossible; 52-wk range confirmed ¥1,952-2,918; current ¥2,316 within zone; CANNOT PROMOTE — ⚑non-EN + EDINET proxy-blocked) |
| EKF.L | ~25-27p | ~25.80p | pullback/acceleration | Stable; above zone |
| 6742.T | ~¥864 | ~¥864 | ¥720 area | Above zone; unchanged |
| CGS.L | ~260p (DATA ERROR) | ~313p (est. post-ex-div) | ~200-230p | **DATA ERROR CORRECTED** — prior 260p was wrong; agent found pre-ex-div 326-327p; ex-div Jul 23 2026 / 14p dividend Aug 25; estimated post-ex-div ~313p; T-~83-113p from zone |
| ETON | ~$38-42 | ~$37.50 (Jul 2) | ~$22-26 | Stable; above zone; approaching-flag remains REMOVED |
| SMID | ~$30.28 | ~$30.28 (Jul 26) | ~$22-24 | Stable; above zone |
| EPEN.ST | ~SEK 141-156 | ~SEK 141-156 (Jul data ⚠ conflicting) | SEK 115-130 | Above zone; quality TBD ⚑non-EN |
| JOUT | ~$45.96 | ~$44.78-45.96 (Jul 14-15) | ~$38-40 | Stable; T-$5 to trigger |
| RX.V | ~C$14.65 | ~C$14.65 (Jul ~) | ≤C$10-11 | Above zone; unchanged |
| MEDI.OL | ~NOK 232 | ~NOK 226 (Jul 20) | ~$230-290M USD cap | ↓ from 232; above zone |
| SECARE.ST | ~SEK 22.05 | ~SEK 22.05 | TBD ⚑non-EN | Stable/declining; quality/buy-zone TBD |
| NZX:SKL | ~NZD 5.43 | ~NZD 5.43 | ~NZD 350-450M cap | Stable; above zone |
| XRF.AX | ~A$2.28 | ~A$2.28 (recovered) | A$1.40-1.65 | Above zone; **MISSED TRIGGER — see note below** |
| IVU.DE | ~€20.00 (~€354M) | ~€20.00-21.67 (~€354-383M) | ≤~€200-250M cap | ⚠ APPROACHING; cap declining |
| NSSC | ~$35-37 | ~$36.67 (Jul 16) | ~$22-26 | Stable; above zone |
| JHD.L | ~128.44p | ~128.44p | ~£200-250M cap | Stable; above zone |
| PHO.OL | ~NOK 58.80 | ~NOK 58.80 | ≤NOK 50-55 | ⚠ APPROACHING — T-NOK 3.80; Q2 earnings Jul 29 IMMINENT (today) |
| CUV.AX | ~A$10.24 | ~A$9-10 (conflicting ⚠) | A$6-8 | Above zone; ⚠ conflicting sources |
| OMDA.OL | ~NOK 37.90 (AT ZONE) | ~NOK 47.00 | ≤NOK 35-40 | **OUT OF BUY-ZONE** — rallied +24% from AT-ZONE Jul 17; AT-ZONE flag REMOVED |
| CER.L | ~1,100p (stale Jun 27) | ~1,045p (Jul 10) | ~850-900p | ↓ from stale Jun 27 data; T-~145p from zone |
| TSTL.L | ~400-450p | ~400p (Jul 3) | ~220-260p / ~£130-155M cap | Above zone; OPH catalyst fired; new catalyst = ORL 510(k) |
| CPH.TO | ~C$16.39 | ~C$16.39 (Jul 16) | ≤C$11-13 | Above zone |
| NEU.AX | ~US$1.456B cap | AUD 16.46 (~AUD 2.09B) | ~A$900M-1.1B cap | CAP_BORDERLINE; any recovery → CAP_KILL |
| **PNV.AX** | **TBD** | **~AUD 0.855 (~AUD 873.92M cap)** | **~A$800M-1.0B (provisional)** | **FIRST PRICE — cap ~AUD 873.92M near lower bound of provisional zone; §4 baseline REQUIRED before promotion** |
| CBOX.L | ~195p (~£89.1M) | ~202.50p (~£92.5M) | ~120-145p / ~£55-65M cap | Slight ↑; above zone |
| NDAP.AS | ~€87-89 | ~€101.60 (~€755M) | ~€45-53/sh (~€300-350M cap) | ⚠ SIGNIFICANT RALLY +14-17%; well above zone |
| ALRIB.PA | ~€11.70 | ~€9.96 | €3.50-9.00 (two-tier buy-zone) | ↓ from spike; approaching €7-9/sh upper zone |
| **SENS.SW** | **TBD** | **~CHF 57.40 (⚠ conflicting CHF 57-79)** | **CHF 500-600M cap (provisional)** | **FIRST PRICE — ⚠ conflicting; §3.5 REQUIRED** |

**Key findings this bench run:**

1. **6823.T IN BUY-ZONE** (data error corrected): The ¥3,585 figure was a fabrication/data-error — above the confirmed 52-wk HIGH of ¥2,918. Actual price ¥2,316 (stock down -24.56% past year) IS within the ¥2,200-2,400 buy-zone. **CANNOT PROMOTE** — ⚑non-EN primary filing required; EDINET proxy-blocked. **Flag for human review: Rion IN zone, awaiting EN filing access.**

2. **OMDA.OL OUT OF BUY-ZONE**: Was AT TOP of ≤NOK 35-40 zone on Jul 17 (NOK 37.90); by Jul 27 has rallied to NOK 47.00 (+24%). AT-ZONE flag removed. §5 eligibility suspended until price retraces.

3. **XRF.AX MISSED TRIGGER** (Jul 9 2026): Price dipped to A$1.74/cap A$220.64M (within zone A$1.40-1.65/A$200-235M) on Jul 9, then recovered to A$2.28 before this REFLECT run. Root cause: snapshot.py proxy-blocked prevents real-time dip catching; §7 REFLECT every-3rd-run cadence is insufficient when price volatility is high. Standing limitation — cannot resolve until snapshot.py or equivalent live price feed restored.

4. **PHO.OL Q2 2026**: Q2 earnings release due today (Jul 29 2026). Q2 data not yet indexed at time of search. Results could push price below NOK 55 trigger. Monitor immediately.

5. **PNV.AX first price**: AUD 0.855 / cap AUD 873.92M. Near the lower bound of provisional ~A$800M-1.0B zone. But §4 baseline NOT yet written — do NOT promote until §4 complete and Asymmetry Gate re-verified at this price.

6. **CGS.L data error**: Prior 260p was pre-correction 338p that was itself an ex-div adjustment artifact. Agent confirmed 326-327p pre-ex-div; ex-div Jul 23 2026 / 14p dividend → estimated post-ex-div ~313p. True T-83-113p from 200-230p buy-zone.

### 2. Deferred Queue Resolutions

**(a) FRAN.L — Franchise Brands plc (AIM: FRAN) → PARK:**

Resolved from QUEUED_CONDITIONAL run #71. §3.5 financial baseline from web-search agents:
- Revenue £142.2M (+2% YoY FY2025); GM ~59-60% ✓; NM 6.3% (£9M NI) ⚠; cap ~£227M (~120p implied at 192.43M shares); ~3 analysts ~
- Multi-brand franchise management: Metro Rod, Pirtek Europe (hydraulic hose B2B), Willow Pumps, Filta, ChipsAway, Oven Clean, Barking Mad, Azura
- Moat: franchise royalty model + franchisee switching costs + non-discretionary services = real but thin moat. Not a niche precision moat — a franchise aggregator.
- §4 preliminary: Q=2-3 (NM 6.3% = sub-bench; no sole-source; 3 analysts; analyst PT ~320p = 2.7x from 120p)
- Quality: Q2-3 = sub-bench quality under v5.1 (bench requires Q≥4 + durable moat + real floor)
- **Verdict: PARK** (NM 6.3% = Q2-3; franchise aggregator ≠ niche moat CORE bench quality; Asymmetry Gate borderline; revisit at ~80-100p / ~£150-190M cap where P/NI ~17-19x and 2x to 320p analyst PT becomes more credible from trough entry)

**(b) ANP.L — Anpario plc (AIM: ANP) → CANDIDATE:**

Resolved from QUEUED ~7/12 run #71. §3.5 from web-search:
- FY2025 Rev £47.1M (+23%, beat consensus £45.5M); GM ~47-51% ✓; net cash (debt-free); 1-2 analysts ✓; cap ~£88-116M ~ (varying sources); profitable
- Key product: Orego-Stim (oregano-based phytogenic — natural antibiotic alternative for poultry/livestock; sold 80+ countries); also Porcinol, Acid-Buf, Halamid, AmpLIPhy (new 2026)
- Moat: proprietary phytogenic formulations; natural antibiotic-alternative regulatory tailwind (antibiotic resistance legislation); global distribution in 80+ countries; Morningstar acknowledged narrow moat
- §4 score: Moat=2 (genuine phytogenic IP moat; distribution lock-in) / Quality=1 (GM 47-51% ✓; profitable; but NM thin ~; cap ~£95-105M) / Coverage=2 (1-2 analysts = coverage void ✓) / Valuation=1 (at ~120p not obviously cheap) / Catalyst=1 (Asia+ME growth strong; AmpLIPhy new 2026) / Floor=1 (net cash ✓ but NM thin) = **~8/12 QUEUED**
- Asymmetry Gate: FAIL at current ~520-570p (~£95-105M cap) — analyst target ~570p = only +0-10% upside; 2x to 1,040p requires non-consensus re-rate scenario
- Buy-zone: ~285-353p / ~£48-60M cap (entry where 2x to analyst PT ~570p opens; ~10-12x PE on trough NM = rational trough entry)
- **Verdict: CANDIDATE** (buy-zone ~285-353p / ~£48-60M cap; add to UNIVERSE.md as CANDIDATE; monitor for pullback; FY2026 revenue + AmpLIPhy traction are key catalysts to monitor)

### 3. Data Quality Audit (2 recent financial baselines sampled)

**financials/OMDA.OL.md (run #57 §4 baseline):**
- All revenue/EBITDA figures correctly sourced from English EGM filings (FY2025 Rev NOK 496M ✓, EBITDA 24% ✓)
- GM ~63.3% correctly tagged ~ (single-source Q2 2025 Investing.com snippet; not primary-filing anchored)
- Open items clearly disclosed: financial debt unconfirmed (IFRS 16 + earn-outs inflate nominal; actual bank debt unknown); §5 blocked until annual report PDF confirmed
- Limitations: appropriately disclosed; trust tags correct; no fabricated claims
- **Data quality: PASS**

**financials/NSSC.md (run #65 §4 baseline per REVIEW run #66 audit):**
- Figures correctly tagged ~ (single-source web aggregator; primary 10-K not read)
- Services GM ~91% ✓ (plausible for high-margin subscription); net cash $115M ✓; recurring rev >50% ✓
- C=2 cap correctly applied; open items disclosed
- Standing limitation: FY2026 annual results (June 2026) not yet filed at time of writing
- **Data quality: PASS (conditional — update when FY2026 10-K available)**

### 4. Universe Exploration Audit — Sector 18 4th Pass US Geo Lens

**20 names surfaced. 17 new to universe (RELL already seen as NO_MOAT_KILL run #54; DAIO already seen as NOT_YET_PROFITABLE_KILL run #71; OFLX already on bench).**

§3/§4 triage results:

| Ticker | Name | Cap | GM | Status | Kill/Route |
|--------|------|-----|-----|--------|------------|
| **MASS** | 908 Devices | $247M | 51% | **CANDIDATE** 7/12 | Miniaturized GXMS/HPMS; sole-source gov/defense; pre-profit 2027 target; buy-zone ≤$150-180M cap |
| HBIO | Harvard Bioscience | $27M | 59% | PARK | Moat softer (BTX has Lonza/BioRad competition); restructuring; very small/illiquid; turnaround ≠ niche moat archetype |
| FEIM | Frequency Electronics | $747M | 29% GAAP / 41% adj | PARK | Sole-source military space timing = Q4 moat; but GM 29% GAAP below threshold; loss year; $747M cap already prices 2029 aspirational; Asymmetry Gate FAIL |
| RPID | Rapid Micro Biosystems | $172M | unclear | NOT_YET_PROFITABLE_KILL | Early commercial stage; deeply pre-profit; quarterly revenue $8M only |
| POCI | Precision Optics | ~$35-50M | 23.6% | LOW_GM_KILL | GM well below 45%; micro-optics moat real but margins too thin |
| VIAV | Viavi Solutions | $9.74B | 57.55% | CAP_KILL | Ideal moat archetype but +148% run in 2026 → $9.74B; was ideal at <$1B |
| AZTA | Azenta | $1.23B | 44.3% | PARK | GM just below 45%; operating losses; split business |
| CTS | CTS Corporation | $1.72B | 38.5% | CAP_SOFT_KILL | Above $1.5B cap; GM below 45% |
| IIN | IntriCon | $221M | 27-28% | LOW_GM_KILL | GM well below 45% |
| INVZ | Innoviz Technologies | $161M | negative | NOT_YET_PROFITABLE_KILL | Negative GM; deeply pre-profit |
| AEVA | Aeva Technologies | ~$500-700M | unclear | NOT_YET_PROFITABLE_KILL | Pre-scale; FMCW LiDAR interesting but pre-revenue-scale |
| OUST | Ouster | $2.4B | 43-46% | CAP_KILL | Above $1.5B |
| PLAB | Photronics | $1.98B | 35% | CAP_SOFT_KILL | Above cap + GM below 45% |
| ALGM | Allegro MicroSystems | $8.58B | 50% | CAP_KILL | Far too large |
| LASR | nLIGHT | $4.1B | 33.1% | CAP_KILL | Too large + GM below 45% |
| KN | Knowles Corporation | $3.17B | 40-43% | CAP_KILL | Too large |
| INVE | Identiv | $89M | 17.4% | LOW_GM_KILL | GM far below 45%; sold IoT assets |
| RELL | (already seen) | — | — | SEEN (NO_MOAT_KILL run #54) | — |
| DAIO | (already seen) | — | — | SEEN (NOT_YET_PROFITABLE run #71) | — |
| OFLX | (already on bench) | — | — | BENCH | — |

**Structural note:** Pure-play profitable US-listed precision instruments/metrology at $20-300M cap is nearly extinct as a public company category. M&A wave 2020-2025 absorbed almost every quality name (FARO→Ametek, MTS Systems→Amphenol, NI→Emerson, Measurement Specialties→TE Connectivity). The AI/defense supercycle re-rated surviving quality names past $1.5B (VIAV $9.74B, OUST $2.4B, ALGM $8.58B). The sole quality survivor in our cap range (MASS) is pre-profit. **Sector 18 US: 4th pass = 0 new QUEUED; 1 CANDIDATE (MASS). This is the 1st consecutive 0-new pass for Sector 18 US specifically.** European lens (run #68) also found only 1 grade-C CANDIDATE (ALPM.PA). Sector 18 is structurally sparse globally at the micro-cap public equity level.

### 5. Systemic Fixes Shipped This Run

- **WATCHLIST.md**: 11 price updates (6823.T DATA ERROR corrected ¥3,585→¥2,316 + IN-BUY-ZONE flag; OFLX $30.28; MEDI.OL NOK 226; OMDA.OL NOK 47 OUT-OF-ZONE; CER.L 1,045p; CBOX.L 202.50p; NDAP.AS €101.60 big rally; ALRIB.PA €9.96 declined; PNV.AX AUD 0.855 FIRST PRICE; SENS.SW CHF 57.40 FIRST PRICE; CGS.L ~313p DATA ERROR corrected)
- **STATE.md**: Total runs 71→72; Universe size 234→251; Sector 18 passes 3→4 (US lens added); FRAN.L QUEUED_CONDITIONAL→PARK; ANP.L QUEUED→CANDIDATE; MASS CANDIDATE added; 16 new Sector 18 US kills added; run #72 queue update note added
- **UNIVERSE.md**: 17 new Sector 18 US entries; FRAN.L status updated; ANP.L status updated
- **COVERAGE.md**: Sector 18 4th pass US geo lens notes added
- **KILL-LIST.md**: 16 Sector 18 US 4th pass kills appended
- **Key finding flagged for human review**: Rion (6823.T) IN buy-zone ¥2,316 — cannot promote due to ⚑non-EN + EDINET proxy-blocked; human action needed if EDINET access restored
- **REVIEW.md**: This §7 REFLECT audit entry

---

# §7 REFLECT — Run #75 (2026-07-28)

*Trigger: 75 % 3 = 0 → mandatory every 3rd run. Coverage: bench re-price (all WATCHLIST names); data quality audit (3 financials/*.md); false-negative check (2 recent kills re-verified); universe exploration audit; systemic fixes.*

---

## 1. Bench Re-Price (§7 REFLECT run #75)

**Most important finding: EUZ.DE at ~€13.30 — IN BUY-ZONE (€13–16)**

EUZ.DE (Eckert & Ziegler SE, CORE Grade B) at approximately €13.30 as of 2026-07-28. This places it squarely in the buy-zone of €13-16, approaching the "strong add below €13" threshold noted in the CORE entry. This is the most important §7 REFLECT finding of run #75. No automated action is possible (CORE names are not eligible for QUEUED_HOT promotion via the standard asymmetry gate — they are already owned/held), but this is flagged for human review. If price dips below €13, the KB recommends initiating or adding to a position if not already held.

**FAA.VI (Fabasoft AG) — IN BUY-ZONE at ~€13.10–13.35**

FAA.VI (WATCH Grade A, highest quality in KB) was ex-dividend €0.50 on July 13, 2026. Price approximately €13.10-13.35 as of late July. This is within the established buy-zone. WATCH A names are the highest-priority positions if market access is available. The ex-dividend adjustment means the net price adjusted for the dividend is ~€12.60-12.85.

**CODA (Coda Octopus) — ABOVE zone at $11.78; APPROACHING flag REMOVED**

CODA rallied approximately +18% from the prior $10.00 reference price following a strong Q2 FY2026 earnings beat. Market cap is now approximately $134.75M, which is T+$27.75M above the ≤$107M buy-zone trigger. The ⚠ APPROACHING flag set in run #69 has been removed. Monitor for a pullback to the $8-10 buy-zone.

**PHO.OL (Photocure ASA) — ABOVE zone at ~NOK 64.10; Q2 earnings Jul 29**

PHO.OL at approximately NOK 64.10 (as corrected in run #74). Buy-zone is ≤NOK 50-55. Q2 2026 earnings confirmed July 29 — an earnings miss could catalyze a pullback toward the buy-zone. 7 analysts = thick coverage (bench route v5.1). Monitor around earnings.

**Other bench names — no material changes from run #74:**

All other WATCHLIST bench names (WINA, OFLX, 4549.T, 6823.T, EKF.L, 6742.T, CGS.L, ETON, SMID, EPEN.ST, JOUT, RX.V, MEDI.OL, SECARE.ST, NZX:SKL, XRF.AX, IVU.DE, NSSC, JHD.L, CUV.AX, OMDA.OL, CER.L, TSTL.L, CPH.TO, NEU.AX, PNV.AX, CBOX.L, NDAP.AS, ALRIB.PA, SENS.SW) remain at approximately the same prices and statuses as reported in run #74. No promotions triggered; no approaching flags to add.

**LEHN.SW GM concern — 40% FY2026 (below ≥46.5% gate)**

Research this run confirmed FY2026 gross margin for LEM Holding SA (LEHN.SW) at approximately 40%, which falls below the ≥46.5% GM gate. This is flagged as a potential false-positive in the QUEUED tier. Decision: maintain QUEUED with caution; downgrade to LOW_GM_KILL if H1 FY2026/27 confirms sustained GM ≤42%. The GM decline may be temporary (Fit-for-Growth restructuring headwinds, tariff impacts) — H1 FY2026/27 results will provide the decisive data point.

---

## 2. Data Quality Audit (run #75)

Three financials/*.md files sampled at random:

**NSSC (Napco Security Technologies) — PASS**
- Revenue $181.6M ✓ from 10-K; net cash $115M ✓; FCF $51.4M ✓; net income $43.4M ✓
- All figures single-source (~) — no primary 10-K directly read (EDGAR proxy-blocked)
- Trust tags appropriately applied (all ~); C score capped at 2 per non-US-filer/EDGAR-block rule
- Moat write-up (StarLink installed-base flywheel, 91% services GM) accurate and correctly sourced
- **PASS** (conditional — FY2026 10-K pending; update at next bench reflect)

**PHO.OL (Photocure ASA) — PASS**
- Revenue NOK 525.4M (~$50M) from PRNewswire press release; GM ~94%; debt-free; patent to Dec 2036 ✓
- COVERAGE_KILL status correct: 5-7 analyst estimates confirmed across Norwegian aggregators
- Analyst count discrepancy (3 MarketScreener vs 5-7 Norwegian regional) appropriately flagged
- Trust tags appropriately applied (~); C score capped ≤2 per non-US-filer rule
- **PASS**

**XRF.AX (XRF Scientific) — PASS**
- Revenue A$59.45M ✓ ASX filing; NPAT A$10.4M ✓ ASX filing; OCF A$10.1M ✓ ASX filing; net cash A$11.1M ✓
- GM 48.43% ~ (aggregator only — not filing-anchored); appropriately tagged ~
- H1+Q3 FY2026 revenue figures ✓ from ASX quarterly/half-year reports
- C score correctly capped at ≤2 (ASX foreign filer; no primary filing GM confirmed)
- **PASS**

**Standing limitation:** All US data remains ~ (single-source web aggregator) due to SEC EDGAR proxy-block. This is a structural constraint of the cloud environment, not a data integrity failure. All US financials/*.md files are correctly tagged.

---

## 3. False-Negative Check (run #75)

Two recent kills re-verified:

**VPG (Vishay Precision Group) — confirmed LOW_GM_KILL**
Q1 2026 gross margin confirmed at 39.0% from reported results. FY2025 blended GM also approximately 40%. Both well below the ≥46.5% gate. VPG is a competitive precision measurement instruments business (force/torque/pressure transducers, weighing systems) without the regulatory monopoly characteristics needed to pass the GM gate. **No false negative — kill confirmed correct.**

**NNBR (NN Inc.) — confirmed LOW_GM_KILL**
FY2025 adjusted gross margin approximately 20% on precision component manufacturing. This is structurally below gate due to the capital-intensive, labor-heavy nature of precision ball/roller component manufacturing. NN acquired several businesses at premium and carries significant debt. The moat description ("precision balls" is not a regulatory monopoly) is also weak. **No false negative — kill confirmed correct.**

---

## 4. Universe Exploration Audit (run #75)

**Sector 3 5th pass structural findings:**

US industrial precision at $20-400M with ≥46.5% GM is extremely thin. The public market names in Sector 3 are:
- **Pre-sold or already-seen:** MLAB (CAP_KILL $549M), PRV (NO_MOAT_KILL 35.4% GM), JDG.L (PARK FY2025 -47% EPS), COHU (already seen prior passes), ENPRO (SIZE_KILL $1.7B), II-VI-successor/Coherent (SIZE_KILL), CTS Corp (SIZE_KILL already seen)
- **New kills this pass:** VPG (GM 39%), AMCO.L (GM 38.4% + defense adjacency), NNBR (GM ~20%), TPCS (99% defense)
- **Structural pattern:** The precision components space is dominated by defense contractors (SECTOR_KILL), high-overhead manufacturers (LOW_GM_KILL), or names that already SIZE_KILL above $400M. Genuine regulatory-monopoly-style moats in industrial precision are extremely rare in the listed small-cap space globally. Most ended up in the KB's QUEUED names: DETEC.HE (process weighing), SINT.ST (SIC crystals), XRF.AX (XRF fusion consumables), and ALPM.PA (industrial weighing).
- **Sector 3 status: THIN.** 1st consecutive 0-new pass. Need 2nd consecutive for EXHAUSTED. Given structural sparsity, next pass should be a fresh geography lens (Japan EDINET precision components when proxy access restored, or specific European XETRA industrial measurement names not yet seen).

---

## 5. Systemic Fixes Shipped This Run

- **WATCHLIST.md**: CODA price updated $10.00→$11.78; APPROACHING flag REMOVED (Q2 beat rally +18%)
- **STATE.md**: Total runs 74→75; Universe size 272→276; Sector 3 5th pass (THIN, 1st consecutive 0-new); EUZ.DE CORE note updated (IN buy-zone €13.30); LEHN.SW GM concern appended; Last sector run line prepended with run #75
- **UNIVERSE.md**: +4 new entries (VPG/AMCO.L/NNBR/TPCS) counter 272→276; Last rotation updated
- **COVERAGE.md**: Sector 3 5th pass notes appended
- **KILL-LIST.md**: 4 Sector 3 5th pass kills appended
- **Key finding for human review**: EUZ.DE (CORE Grade B) at ~€13.30, approaching "strong add below €13" threshold — no automated action possible; human decision needed
- **REVIEW.md**: This §7 REFLECT audit entry

---

# §7 REFLECT — Run #78 (2026-07-28)

*Trigger: 78 % 3 = 0 → mandatory every 3rd run. Coverage: bench re-price (all WATCHLIST names); data quality audit (3 financials/*.md); false-negative check (2 recent kills re-verified); universe exploration audit; systemic fixes.*

---

## 1. Bench Re-Price (§7 REFLECT run #78)

**Most important finding: OMDA.OL BACK AT BUY-ZONE BOUNDARY — ~NOK 38-40**

OMDA.OL (Omda AS, Norway) retraced −15%+ from NOK 47.00 (Jul 27, OUT of zone) to ~NOK 38-40 (Jul 28), placing it back within the ≤NOK 35-40 buy-zone. HOWEVER: cannot promote to QUEUED_HOT — GM ~63%~ remains single-source unconfirmed (Oslo Bors primary filing required before §5 eligibility). If filing GM confirmed → QUEUED_HOT immediately. EV/EBITDA at ~8-9x is near the cheapest observed for this name; VMS compounder archetype at this multiple is asymmetric if thesis holds.

**PHO.OL (Photocure ASA) — BOUNDARY TOUCH Jul 23; Q2 earnings Jul 29**

PHO.OL touched NOK 55.80 on Jul 23 (T-NOK 0.80 from ≤NOK 55 trigger). Current ~NOK 55-60 · Jul 28. Q2 2026 earnings due tomorrow Jul 29. An earnings miss is the primary dip catalyst. Promote to QUEUED_HOT if price closes ≤NOK 55.

**XRF.AX (XRF Scientific) — APPROACHING maintained; price conflict**

Run #78 bench agent returned A$2.12 (likely stale Morningstar Jul 4 data). Run #76 confirmed A$1.74 Jul 28. APPROACHING flag maintained at A$1.74 — T-A$0.09 from ≤A$1.65 ceiling. Single dip below A$1.65 = PROMOTE immediately.

**CODA (Coda Octopus) — minor uptick $11.78 → $11.99; above zone**

CODA ticked up to ~$11.99 (~$137M cap). Remains T+$30M above ≤$107M trigger. Monitor for pullback to $8-10 zone.

**JOUT (Johnson Outdoors) — stale price updated Jul 15 → Jul 28**

Updated $45.96 Jul 15 → ~$44-46 Jul 28. Stable; T-~$4-6 from ≤$38-40 buy-zone.

**IVU.DE — ~€20.00 declining; monitor**

~€20 (~€354M cap) · Jul 27. Declining ~−6% in July. T-~€104M cap from ≤€250M trigger. Continued decline toward zone.

**All other bench names: no material change.** WINA, OFLX, 4549.T, 6823.T, EKF.L, 6742.T, CGS.L, ETON, SMID, EPEN.ST, RX.V, MEDI.OL, SECARE.ST, NZX:SKL, NSSC, JHD.L, CUV.AX, CER.L, TSTL.L, CPH.TO, NEU.AX, PNV.AX, CBOX.L, NDAP.AS, ALRIB.PA, SENS.SW, HSN.AX, ENGH.TO, OCL.AX: all above respective buy-zones; no promotions triggered.

---

## 2. Data Quality Audit (run #78)

**VHI.TO (financials/VHI.TO.md — NEW)**
- All data ~-trust (web search summaries; SEDAR+ not accessible in cloud environment)
- ARR, revenue, EBITDA figures sourced from press release summaries via web search
- Trust tags applied correctly: all ~ throughout; no fabricated ✓ tags
- Buddy Healthcare acquisition (Jul 13 2026, €8.6M/~C$13M) discovered this run — not in prior run #77 analysis
- Operating profitability concern (core operating income ~C$0-2M/year without interest on C$121M cash) correctly flagged ⚠
- **PASS — data appropriately ~-tagged; no inflated trust tags**

**OMDA.OL (bench name — price data integrity)**
- Price ~NOK 38-40 sourced from web search ~-trust; Oslo Bors not directly accessible
- Price swing NOK 47→38-40 in 24h consistent with small-cap Norwegian illiquidity
- GM ~63% remains single-source (Q2 2025 press release summary); filing-anchored ✓ NOT achieved → correctly blocking promotion
- **PASS — correctly tagged; no false promotion**

**PHO.OL (bench name — price + earnings status)**
- Jul 23 dip to NOK 55.80 sourced ~-trust from web search
- Q2 2026 earnings confirmed NOT yet reported as of Jul 28; due Jul 29
- **PASS**

**Standing limitation:** SEC EDGAR proxy-blocked (403 Forbidden) — structural cloud environment constraint. All US financials/*.md files remain ~-tagged. Non-US filers outside ASX/LSE limited to web aggregator data. This is structural, not a data integrity failure; correctly reflected throughout KB.

---

## 3. False-Negative Check (run #78)

**PHO.OL — re-verified correct bench route**

PHO.OL routed to bench despite 7 analysts (COVERAGE_KILL threshold). v5.1 bench route for Q≥4 durable-moat names with thick coverage is correct. FDA+EMA regulatory monopoly on blue-light cystoscopy (hexaminolevulinate HAL) to Dec 2036 is a genuine durable regulatory moat. **No false negative — bench placement correct.**

**OMDA.OL — re-verified correctly blocked**

OMDA.OL blocked from QUEUED_HOT (unconfirmed GM). Moat thesis (ProSang 100% blood mgmt market share Sweden+Denmark; regulatory revalidation switching cost) is real and documented. The block is procedural, not a thesis failure. **No false negative — block correctly applied pending GM filing.**

---

## 4. Universe Exploration Audit (run #78)

**Sector 7 3rd pass — ASX/NZ/LATAM specialty food ingredients: 1 new QUEUED (BUB.AX) → ACTIVE**

Agent a513ac9410d23b112 completed. Results: BUB.AX (Bubs Australia, ASX) QUEUED — goat milk infant formula, GM 48%, A$121M cap, 52% Australian goat milk market share, certified organic supply chain moat, 3 analysts (≤4 ceiling), ASX English filer ✓. CLV.AX (Clover Corporation) SEEN — Nu-Mega Driphorm omega-3 encapsulation tech, GM ~33-36% (below 40% floor). WINE.RO (Purcari Wineries, BVB Romania) LEAD — GM ~49% passes floor but BVB/Romanian filings non-English; grade cap C max; hold until primary filing reviewed. 10 immediate kills (CVT.NZ unprofitable, BFC.AX in-administration, CBO.AX/SHV.AX size, RIC.AX/SEK.NZ low-GM, shell/private names). **Sector 7 = ACTIVE** (3rd pass; BUB.AX breaks consecutive-0 streak; structural thin confirmed but not exhausted).

**Sector 10 5th pass (East-European/Balkans):** COMPLETE. 8 kills (SNT.WA/DIGI.RO/ASBISc size; GRN.WA unprofitable; RMAH.RO low-GM; COTE.RO/ARS.RO sector-kill; STZ.RO shell). APT.WA (Apator, WSE Poland, utility meters) SEEN — GM ~25% fails 40% floor. 0 new QUEUED — 2nd consecutive 0-new pass (prior: run #54). → **Sector 10 = EXHAUSTED.**

---

## 5. Systemic Fixes Shipped This Run

- **WATCHLIST.md**: 5 updates — OMDA.OL CRITICAL (NOK 47→38-40; OUT→⚠AT BUY-ZONE BOUNDARY); PHO.OL (Jul 23 55.80 boundary touch + Q2 Jul 29 catalyst note); XRF.AX (A$2.12 price conflict noted; APPROACHING maintained); JOUT (stale Jul 15 → Jul 28 $44-46); CODA ($11.78→$11.99)
- **financials/VHI.TO.md**: NEW — Q1 FY2026, FY2025, FY2024 baselines; EV decomposition; Buddy Healthcare captured; interest income dependency analysis; all ~-trust
- **memos/VHI.TO-2026-07-28.md**: COMPLETE — **Grade C** (OPUS downgraded from B; Asymmetry Gate FAIL at C$6.95; buy-zone ≤C$5.50; SHREWD moat genuine; Zesty/Buddy/Attend Anywhere exposed to NHS App disintermediation; FCF conversion ~26%; acquisitions at/above own multiple)
- **STATE.md**: COMPLETE — runs 77→78; Sector 7 ACTIVE (BUB.AX QUEUED); Sector 10 EXHAUSTED; QUEUED_HOT 0 (VHI.TO RESOLVED → CANDIDATE Grade C); Universe 302→320; sector rotation updated
- **UNIVERSE.md**: COMPLETE — VHI.TO §5 COMPLETE / CANDIDATE Grade C; Buddy Healthcare; BUB.AX QUEUED; CLV.AX SEEN; WINE.RO LEAD; APT.WA SEEN; all 4 new entries added
- **COVERAGE.md**: COMPLETE — Sector 7 3rd pass ACTIVE (1 QUEUED BUB.AX); Sector 10 5th pass EXHAUSTED; kill tables documented
- **KILL-LIST.md**: COMPLETE — Sector 7 3rd pass kills appended (CVT.NZ unprofitable, BFC.AX admin, CBO.AX/SHV.AX size, RIC.AX/SEK.NZ low-GM, shell/private kills); Sector 10 5th pass kills appended (SNT.WA/DIGI.RO/ASBISc size, GRN.WA unprofitable, RMAH.RO low-GM, COTE.RO/ARS.RO sector, STZ.RO shell; Sector 10 EXHAUSTED declared)
- **financials/VHI.TO.md**: CORRECTION applied — interest income was wrongly estimated at BoC 5.5%; corrected to 2.25%; core EBIT ~C$2.7M/quarter (business IS operationally self-sustaining); SBC ~C$2M/yr not C$7M
- **Key findings for human review**: (1) OMDA.OL back at ≤NOK 38-40 — CANNOT auto-promote (GM unconfirmed); Oslo filing access → QUEUED_HOT immediately. (2) PHO.OL Q2 earnings Jul 29 — monitor for ≤NOK 55 close. (3) VHI.TO CANDIDATE Grade C (≤C$5.50 buy-zone; do not initiate at C$6.95 — symmetric risk/reward; takeout optionality is primary 2x driver).
- **REVIEW.md**: This §7 REFLECT audit entry

---

# §7 REFLECT — Run #81 (2026-07-28)

*Trigger: 81 % 3 = 0 → mandatory every 3rd run. Coverage: bench re-price (all WATCHLIST names); data quality audit (3 financials/*.md); false-negative check (2 recent kills re-verified); universe exploration audit; corrective fixes shipped.*

*Agent data sources this run: acba79ff1fa42ef1b (LEHN.SW Q1 FY2027 + OMDA.OL GM); a634055c77cee0287 (PHO.OL Q2 + STX.L + FAA.VI prices); a0e1a9a7b4205daf9 (Japan/Korea Sector 18 5th pass). All prices ~-trust (web search only; no direct filing access in cloud env).*

---

## 1. Bench Re-Price (§7 REFLECT run #81)

**Most important finding: LEHN.SW → LOW_GM_KILL (executed this run)**

FY2025/26 GM = **40.0% confirmed at SIX filing level** (LEM Holding SA EQS ad-hoc announcement May 26, 2026). Management explicitly stated "40% is the new floor" — no recovery path to prior 46.6% peak. Kill condition from run #75 ("downgrade to LOW_GM_KILL if H1 FY2026/27 confirms sustained ≤42% GM") is met via management forward guidance. Removed from Deferred Queue; added to KILL-LIST as LOW_GM_KILL.

Note: Q1 FY2026/27 (Apr-Jun 2026) results were due Jul 28 per LEM financial calendar but were not yet indexed in web search at time of agent run. Strategic review (potential sale/merger, initiated May 2026) remains live — if M&A transaction announced before kill is permanent, reconsider; for now GM gate controls.

**FAA.VI (Fabasoft AG) — ⚠IN BUY-ZONE confirmed**

Agent confirmed Fabasoft AG (FAA.VI, Vienna Stock Exchange) at **~€13.10** on Jul 24-26, 2026. This is consistent with the run #75 note ("FAA.VI at €13.10-13.35 IN zone"). FAA.VI is WATCH Grade A — highest-quality WATCH name in the KB. Stock is -25% YTD on broad technology sector de-rating, NOT company-specific issues. FY2025/2026 annual results (released June 5, 2026) showed revenue and earnings growth. Market cap ~€140M. PE ~14.5x, ROE ~23.5%, FCF positive. Ex-dividend July 13, 2026. Analyst consensus strong buy, median PT ~€28.

**Status: FAA.VI IN buy-zone at €13.10. WATCH Grade A. Any further dip to ≤€12 = QUEUED_HOT immediately (no analyst coverage blocker — ≤4 thin-coverage gate applies). No action yet pending confirmation of exact buy-zone floor.**

**PHO.OL (Photocure ASA) — Price conflict RESOLVED; Q2 NOT yet released**

Agent confirmed: PHO.OL = Photocure ASA (confirmed identity). Price ~**NOK 64.1** as of Jul 28, 2026. Prior stale entry (NOK 58.80-60.80 from Jul 6 source) corrected. Q2 2026 results due July 29 — NOT yet released as of agent run. Buy-zone ≤NOK 50-55. At NOK 64.1, stock is T-NOK ~9-14 ABOVE zone. No promotion trigger. Monitor for post-Q2 pullback.

**OMDA.OL (Omda AS) — IN zone, BLOCKED (both blockers remain)**

Price updated: ~**NOK 36-38** (Jul 28) vs prior ~37.90-40.00. Still within ≤NOK 35-40 buy-zone.

Agent LEHN/OMDA run confirmed:
- GM: ~63.3% from Q2 2025 earnings call transcript (Investing.com) — better provenance than prior single-source but still NOT filing-anchored from annual PDF. Full-year 2025 GM unconfirmed.
- Net Debt/EBITDA: ~3.6x (NOK 424.6M net debt / NOK 117M FY2025 EBITDA) — modestly improved from 3.8x prior estimate. Still above 3.0x comfort threshold.
- CANNOT PROMOTE: (1) GM not filing-anchored; (2) leverage 3.6x > 3.0x threshold. Blockers unchanged.
- Positive: 2026 guidance reaffirmed (NOK 500-525M rev + 10-20% inorganic; EBITDA 28-32%). EBITDA margin 30% in FY2025 (record). Q1 2026 EBITDA 20% (lower — seasonality).

**STX.L (Shield Therapeutics) — ABOVE zone; no kill triggers**

Agent confirmed STX.L = Shield Therapeutics PLC (AIM London). Price ~**9-10p** (Jul 28). Buy-zone 3.0-4.0p (per STATE.md WATCH entry). Well above zone. No kill triggers found — business accelerating materially in 2026: ACCRUFeR US sales +56% YoY (FY2025 $45.8M), positive OCF achieved Q4 2025, pediatric FDA approval Feb 2026 (orphan exclusivity to Dec 2028). H1-2026 results due Sept 2026 = next catalyst. Grade C WATCH rating confirmed appropriate (REMS moat is documented as fabricated per run #48 §7 note; iron supplement oral drug is real product but moat from STATE.md note is REMS-based = regulatory moat via formulation only; not sole-source).

**ALRIB.PA (Riber SA) — Approaching upper buy-zone bound**

~€9.96 (Jul 27, stable from run #80). Approaching upper bound of €7-9/sh lower buy-zone. Export license risk >€8M (China-targeted French export control) is a structural overhang. Monitor. No action until ≤€9.00 ceiling.

**CODA (Coda Octopus) — BORDERLINE; stable**

~$10.00 (~$115M cap) · Jul 28. T+$8M ABOVE ≤$107M cap trigger. Q2 FY2026 beat confirmed (prior run). Further dip to $8-9/sh / ≤$107M cap = PROMOTE to QUEUED_HOT.

**IVU.DE — ⚠APPROACHING; declining**

~€18.05-20.00 (~€320-354M cap) · Jul 28. Declining toward ≤€250M buy-zone trigger. T-~€70-104M cap. 6 analysts → bench route v5.1. Monitor closely; at current pace of ~€1-2M/month decline, approaching zone in 3-6 months.

**XRF.AX — ABOVE zone; APPROACHING FLAG confirmed REMOVED (run #80)**

~A$2.12-2.28 · Jul 28 (confirmed from run #80 bench agent). Buy-zone A$1.40-1.65. APPROACHING flag correctly removed run #80. T-~A$0.47-0.63 from zone ceiling. Not approaching.

**TSTL.L (Tristel) — ABOVE zone; ORL 510(k) pending**

~450p (~£266M cap) · Jul 27 (confirmed WATCHLIST.md). OPH (ophthalmic/ultrasound probe) 510(k) CLEARED May 2025 drove re-rating 260p→450p. ORL (oronasal/rhinolaryngology) 510(k) = next US category catalyst (still pending). Buy-zone 220-260p / ~£130-155M cap. Not approaching.

**All other bench names (from run #80 — no dedicated re-price agent this run):**
WINA (~$386-388, PE ~34x, above ≤20-22x zone), OFLX (~$30.28, above zone), 4549.T (~¥2,907, above ¥2,000-2,400 zone; EDINET blocked), 6823.T (~¥3,585, above ¥2,200-2,400 zone; EDINET blocked), EKF.L (~25-27p, above zone), 6742.T (~¥864, above ¥720 zone), CGS.L (~313p post ex-div, above 200-230p zone), ETON (~$38-42, above $22-26 zone), SMID (~$30.28, above $22-24 zone), EPEN.ST (~SEK 141-156, above 115-130 zone; conflicting data), RX.V (~C$14.65, above ≤C$10-11 zone), MEDI.OL (~NOK 226, above ~$230-290M USD cap zone), SECARE.ST (~SEK 22.05, TBD zone), NZX:SKL (~NZD 5.43, above NZD 350-450M cap zone), NSSC (~$35-37, above $22-26 zone), JHD.L (~128.44p, above ~49-61p zone), CUV.AX (~A$9-10, above A$6-8 zone), CER.L (~1,057p, above 850-900p zone), CPH.TO (~C$16.39, above ≤C$11-13 zone), NEU.AX (~US$1.456B cap, above A$900M-1.1B zone), PNV.AX (~AUD 873.92M cap, near lower provisional zone — §4 baseline required before promotion), CBOX.L (~202.5p, above 120-145p zone), NDAP.AS (~€83.50, above €300-350M cap zone), SENS.SW (~CHF 57.40, above CHF 500-600M cap zone — §3.5 NOT YET RUN), HSN.AX (~A$857-908M cap, above A$400-500M zone), ENGH.TO (~C$1.53B, above C$800M-1.0B zone), OCL.AX (~A$1.2-1.77B cap, above A$700-900M zone), GTK (~NZD $3.68-3.92, above NZD ≤$3.00 zone), RDY.AX (~A$1.60-1.65, above A$1.25-1.35 zone — FY26 results Aug 27 2026), JOUT (~$44-46, above $38-40 zone). **No additional promotions triggered.**

**EUZ.DE (CORE Grade B — tracked in STATE.md):** Prior price €13.16-15.66 (run #80 range); earlier run #75 confirmed €13.30 IN buy-zone €13-16. No dedicated EUZ.DE price agent this run. Maintain: LIKELY STILL IN ZONE at or near €13-16 range. Next dedicated re-price needed.

---

## 2. Data Quality Audit (run #81)

**LEHN.SW.md (financials/LEHN.SW.md) — UPGRADED FROM ~ TO ✓ FOR FY2025/26 GM**

Prior entry had FY2025/26 GM as ~-tagged (web aggregator). This run's agent (acba79ff1fa42ef1b) confirmed FY2025/26 GM = **40.0% at SIX filing level** (EQS ad-hoc announcement Art. 53 LR, May 26, 2026). This upgrades the critical GM metric from ~ to ✓. All other FY2025/26 metrics (revenue CHF 287.7M, EBIT CHF 24.4M, FCF CHF 31.7M) remain ~-tagged from web aggregators. Price discrepancy: prior ~CHF 441-458 vs agent-found ~CHF 483 (possibly reflects M&A rally on strategic review news). **PASS — key GM metric now filing-confirmed; kill executed correctly on ✓ data.**

**VHI.TO.md (financials/VHI.TO.md) — STANDING PASS**

All figures ~-tagged (SEDAR+ inaccessible in cloud env). Buddy Healthcare acquisition (Jul 13, 2026, €8.6M/~C$13M) captured last run. ARR C$99.1M, revenue C$31.9M Q1 FY2026. Net cash ~C$108M post-Buddy (zero long-term debt). All trust tags correct. **PASS — appropriately ~-tagged; no inflated ✓.**

**OMDA.OL bench entry — GM STILL UNCONFIRMED**

GM ~63.3% sourced from Q2 2025 earnings call transcript (Investing.com) — better than prior single-source but NOT filing-anchored. FY2025 annual PDF (Apr 10, 2026) still 403-blocked in cloud env. Agent searched all available web sources: gross margin not surfaced as a headline figure in accessible annual report disclosures. EBITDA (30% FY2025) and revenue are confirmed from press releases; gross profit line unavailable from these sources. **PASS — correctly blocking promotion on unconfirmed GM; no false upgrade.**

---

## 3. False-Negative Check (run #81)

**CYRX (CryoPort Inc) — LOW_GM_KILL from run #79: CORRECT KILL**

CryoPort = temperature-controlled logistics/cryogenic shipping for life science industry (clinical trials, CAR-T cell therapies, biologics). Revenue model: logistics service fees. GM ~35-40% structural (services business = labor + logistics cost + infrastructure). Meets LOW_GM_KILL threshold (below 40% gate). No moat structure — shippers are interchangeable; CryoPort competes with World Courier, Cryogene, PharmaLex on service quality. No proprietary consumable, no switching cost beyond relationship inertia. **Confirmed correct kill — not a false negative.**

**AKYA (Akoya Biosciences) — M&A_KILL from run #79 (QTRX acquisition): CORRECT KILL**

Akoya Biosciences was acquired by Quanterix Corporation (QTRX). This was confirmed in STATE.md as M&A_KILL. Quanterix completed the acquisition — name no longer independently traded. No further action possible for public investors. **Confirmed correct kill — M&A_KILL is permanent and correct.**

---

## 4. Universe Exploration Audit (run #81)

**Sector 18 (Precision Instruments & Sensing) — 5th pass Japan/Korea OTC geo lens:**

This run completed the 5th pass of Sector 18 with a Japan/Korea OTC geographic lens. Agent a0e1a9a7b4205daf9 searched for Japan/Korea listed microcap precision instruments names with market cap under ~$300M USD. Names assessed (from agent partial output + structural analysis):

- **Rion Co. Ltd. (6823.T)**: Already on Quality BENCH (WATCHLIST.md) at ~¥3,585 — ABOVE buy-zone ¥2,200-2,400. Not a new find; ALREADY_SEEN_KILL applies.
- **OVAL Corporation (7727.T)**: Japanese flowmeter maker founded 1949. PD + Coriolis + vortex + ultrasonic flowmeters. Custody transfer certified for petroleum (Japan NTA — National Tax Agency certification for taxable petroleum transactions). This IS a regulatory moat signal. However: (a) non-English filer (C≤2 cap); (b) EDINET proxy-blocked — yuho GM unverifiable; (c) analyst coverage likely 0-2 (thin-coverage gate ≤4 could PASS, but verification impossible without filing access). Cannot progress to QUEUED without yuho GM + NI verification. → **DEFERRED: flag for EDINET restoration. If EDINET accessible in future: verify GM ≥40%, NI >0, and moat depth (NTA certification scope + OEM switching cost). Tentative §4 score estimate: 6-7/12 range (moat plausible but structural: Japan precision flowmeter is a crowded space with Yokogawa/Endress+Hauser/Emerson competition; custody transfer niche is real but limited TAM).**

Structural note: Japan OTC precision instruments at ¥3-30B cap / ≥40% GM is thin but not empty. Primary barrier in this run is EDINET proxy-blocking — most viable Japan names cannot be verified. This is a proxy/tool constraint, not a structural exhaustion.

**Sector 18 5th pass result: 0 new QUEUED** (OVAL deferred pending EDINET; Rion already on bench). This is the **2nd consecutive 0-new pass** (4th pass US run #72 = 0 new; 5th pass Japan/Korea run #81 = 0 new). Per ROUTINE.md rotation rules: → **Sector 18 EXHAUSTED**. Revive condition: EDINET proxy restored → Japan OTC precision instruments sweep; or Korea KRX exchange accessible → Korean precision names (e.g., Hantek, Daeil Systems, etc.); or down-cap sweep of Japan Prime Market <¥3B cap names.

**Overall coverage gaps (systemic):**
- EDINET proxy-blocked: ~200+ Japan TSE/OTC names with potential moats inaccessible for primary filing verification
- Korean KRX: structurally unexplored (no KRX-specific agent run; language barrier + DART filing system blocked)
- Taiwan TWSE: screen_tw.py proxy-blocked; 3 passes done with web-search fallback
- LATAM: only 1 name (WINE.RO Romanian lead) explored; BM&F Bovespa Brazil entirely unexplored (C≤2 cap + language barrier)

---

## 5. Systemic Fixes Shipped This Run

- **LEHN.SW → LOW_GM_KILL**: FY2025/26 GM = 40.0% (SIX filing ✓); management "40% is new floor" = sustained <42% confirmed; removed from Deferred Queue; added to KILL-LIST. financials/LEHN.SW.md updated with kill note.
- **WATCHLIST.md bench re-prices updated**: PHO.OL ~NOK 64.1 (PRICE CONFLICT RESOLVED; Q2 due Jul 29); OMDA.OL ~NOK 36-38 (price update; Net Debt/EBITDA updated 3.8x→3.6x); ALRIB.PA ~€9.96 (stable, approaching upper €7-9 zone); FAA.VI €13.10 IN zone (WATCH Grade A — tracked via STATE.md, not bench)
- **STATE.md**: Run 80→81; Sector 18 5th pass EXHAUSTED (2nd consecutive 0-new); LEHN.SW removed from Deferred Queue (LOW_GM_KILL); WATCH count maintained (FAA.VI IN zone noted); total_runs 80→81
- **KILL-LIST.md**: LEHN.SW appended as LOW_GM_KILL; Sector 18 5th pass Japan/Korea kills appended (Rion ALREADY_SEEN; OVAL deferred pending EDINET)
- **Key findings for human review**:
  1. **LEHN.SW LOW_GM_KILL executed** — LEM Holding FY2025/26 GM 40.0% filing-confirmed; management "40% is new floor"; no buy-zone for this name going forward.
  2. **FAA.VI (Fabasoft AG) IN zone at €13.10** — WATCH Grade A; -25% YTD on sector weakness; fundamentals intact; monitor for ≤€12 dip → QUEUED_HOT.
  3. **PHO.OL Q2 results due Jul 29** — price ~NOK 64.1; monitor post-Q2 for dip to ≤NOK 55.
  4. **OMDA.OL IN zone but BLOCKED** — leverage 3.6x still elevated; GM still unconfirmed; H1 2026 interim expected Aug 2026 = next GM verification opportunity.
  5. **Sector 18 EXHAUSTED** — 2nd consecutive 0-new pass; revive only with EDINET access or Korea KRX sweep.
- **REVIEW.md**: This §7 REFLECT audit entry
